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ABSTRACT (ITA) 
 
L’Amiloidosi da catene leggere (AL), è la più comune amiloidosi sistemica. Questa patologia porta 
all’aggregazione delle catene leggere delle immunoglobuline (CL), le quali esplicano proteo-tossicità 
in organi target. Le CL sono fra di loro caratterizzate da alta variabilità di sequenza, generatasi a 
livello genomico, in risposta alla ricombinazione VDJ. In questo senso, è possibile affermare che in 
ogni paziente la malattia venga causata da una determinata CL (Merlini, 2017). Quest’alto livello di 
complessità rende ad oggi poco chiari i determinanti molecolari che causano l’aggregazione e la 
proteo tossicità delle CL. Di conseguenza, studi su questi meccanismi richiedono l’analisi di un ampio 
gruppo di casi per consentire la generalizzazione, con valenza statistica, delle osservazioni. Il nostro 
approccio considera diverse proprietà biofisiche e strutturali delle CL mediante l’utilizzo di varie 
tecniche spettroscopiche, proteolisi limitata e diffrazione ai raggi X. Inoltre, in questo lavoro si fa 
riferimento ad un set di tredici proteine, con sequenze molto diverse tra loro. Fanno parte del 
gruppo di CL: otto CL amiloidogeniche, le quali provocano gravi sintomi cardiaci in pazienti AL e 
cinque non amiloidogeniche. In particolare, le CL non tossiche sono isolate e purificate, da pazienti 
affetti da mieloma multiplo nel quale le CL sono over-espresse ma non mostrano nessun segno 
d’aggregazione o tossicità. 
I dati qui presentati, mostrano che la bassa stabilità di folding e l’alta flessibilità tendono a correlare 
con la proprietà amiloidogenica delle CL studiate. Le caratteristiche strutturali e di idrofobicità, 
invece, non sembrano avere un ruolo nel definire la propensione all’aggregazione. 
Inoltre, da precedenti studi si sa che la tossicità delle CL in vivo è collegata alla presenza di rame. In 
particolare, la relazione fra rame e CL aumenta la produzione di specie radicali dell’ossigeno e il loro 
seguente danno mitocondriale (Diomede et al., 2017a). I nostri dati mostrano che le CL 
amiloidogeniche interagiscono con il Cu2+ con una maggiore affinità, rispetto a quelle non 
amiloidogeniche. In particolare, abbiamo evidenziato che le Istidine possano mediare l’interazione 
CL – ioni rame. Infatti, il legame fra CL e rame perde di affinità in presenza di Istidine protonate. 
Inoltre, i nostri dati suggeriscono che le CL acquisiscono flessibilità e perdono stabilità in presenza 
di rame. 
Il nostro approccio ci ha permesso quindi di concludere, che la propensione all’aggregazione delle 
CL non può essere descritta da un singolo parametro ma dalla concomitante azione di più tratti 
biofisici. Inoltre, questi dati suggeriscono che la tossicità in vivo possa essere dovuta all’alterazione 
delle proprietà intrinseche delle CL facilitata dalla presenza del rame.  
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ABSTRACT (ENG) 
 
Herein, immunoglobulin light chains (LCs) native state was studied in the context of the pathology 
known as light chain amyloidosis (AL). This pathology is characterized by LCs overexpression, which 
leads to toxicity and aggregation into amyloid fibrils in target organs, with heart being the most 
affected one. Due to genetic rearrangement and somatic hypermutation, virtually, each AL patient 
presents a different amyloidogenic LC (Merlini, 2017). Because of such complexity, the fine 
molecular determinants of LC aggregation propensity and proteotoxicity are, to date, unclear; 
significantly, their decoding requires investigating large sets of cases. This project is aimed to 
unravel the molecular determinants linked with LCs toxicity. First we screened several independent 
biophysical and structural properties of the LCs native state. In particular, we considered 
hydrophobicity, fold stability, flexibility and 3D structure.  
Our experimental approach considered two LCs sets called ‘H’ and ‘M’. The H set is composed of 
eight LCs from AL patients while the M set by LCs from multiple myeloma (MM) patients. M LCs 
were chosen as control since they are overexpressed as the toxic H LCs but they do not lead to 
toxicity or aggregation. To date, the molecular bases leading to LC proteotoxicity remain to be 
elucidated. Our data show that low fold stability and high protein flexibility correlate with 
amyloidogenic LCs, while hydrophobicity, structural rearrangements and nature of the LC dimeric 
association interface (as observed in seven crystal structures here presented) do not appear to play 
a significant role in protein aggregation.   
Additionally, it has been demonstrated that the LCs toxicity in vivo is linked to copper (Cu2+) 
(Diomede et al., 2017a) by increasing the radical oxygen species (ROS) production. We aimed our 
studied to clarify Cu2+ LCs interaction. Moreover, we wanted to assess whether Cu2+ is able to alter 
the biophysical properties of the native state to more aggregation prone states. Our findings reveal 
that H LCs interacts with Cu2+ with a higher affinity than M LCs and that His residues may be involved 
in Cu2+ binding. Indeed the affinity decreases in presence of protonated His residues. Moreover, 
data suggest that the interaction with Cu2+ increases the molecular flexibility and decreases the fold 
stability. 
These observations suggests that protein aggregation cannot be evaluated through one single 
parameters but by the co-action of several biophysical traits. Moreover, our results suggest that the 
presence of Cu2+ can alter the native LCs properties leading to a higher toxicity in vivo. 
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Aim of the work 
 
This work is aimed to elucidate the molecular determinants of the H LCs aggregation propensity and 
in vivo toxicity. Herein, we considered the LCs biophysics and structure and the effect of Cu2+ on H 
LCs. In order to reach this aim, we analyzed fold stability, hydrophobicity, protein flexibility, 
molecular interactions and 3D structures. In particular, these properties may be relevant for protein 
misfolding and subsequently aggregation. However, our approach also account for high sequence 
variability, making our data generalizable LC traits.  
The biophysical and structural characterizations were performed with the final aim to reveal traits 
specific for H LCs. Then, starting from these data, we elucidate whether and how Cu2+ could alter 
these specific H LCs properties. 
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1 INTRODUCTION: 
 
1.1 Immunoglobulin and light chains 
 
Immunoglobulins (Ig) are proteins involved in the adaptive immune system which is activated when 
pathogens succeed in evading the innate immune system (Charles A Janeway et al., 2001). Igs are 
hetero-tetramers composed by two heavy chains (HC) and two light chains (LC). Specifically, both 
HC and LC can be functionally separated in two regions: the variable one and the constant one 
(Figure 1.1). In particular, both LC and HC present a variable region composed by one variable 
domain (Vl for the LC and Vh for the HC). Instead, the constant region in LC is composed by one 
constant domain (Cl) and in HC by three constant domains (Ch) (Schroeder and Cavacini, 2010). 
Remarkably, VL and Vh are characterized by a pronounced sequence variability which enables 
different Igs to interact with specific antigens (Charles A Janeway et al., 2001).   
LCs are produced by clonal plasma cells (Weiss et al., 2016) in the bone marrow (BM). They can be 
secreted as homodimers or can be assembled with the HC in order to form complete Igs. LCs present 
a typical oligomerization state according to their isotype. Indeed, these proteins are classifiable in 
two isotypes called k LCs and λ LCs, which are principally different in the C-terminal portion. 
Specifically, λ LCs are always secreted as disulfide-linked homodimers (Waldmann et al., 1972). To 
date, λ LCs are known to be the most represented LCs population  in the context of the pathology 
called light chain amyloidosis (AL). Therefore, if no otherwise stated, herein the term LC will be 
referred to the λ isotype. 
 
Figure 1.1: Schematic representation of an overall immunoglobulin structure.  
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1.1.1 Light chain structure 
 
The full length (FL) LC monomer (~ 22KDa), as already reported in the previous paragraph, presents 
two immunological domains: VL and Cl. Specifically, VL is the N-terminal domain (amino-acids 1- 
110) followed by CL one (amino-acids 115-215) and they are joined together by a linking region 
(amino-acids 111-114) (Bourne et al., 2002; Morgan and Kelly, 2016) (Figure 1.2).  
 
 
Figure 1.2: LC homodimeric structure. Chain A is represented in blue, Chain B in red. (PDB 1A8J) 
(Adapted from Edmundson and Manion, 1998). 
 
Both CL and VL share a β-sandwich topology with eight strands (A, B, C, C’, D, E, F, and G) arranged 
in a Greek key motif (Pokkuluri et al., 1999) (Figure 1.3). Each domain is characterized by the 
presence of an intramolecular disulfide bridge (S-S) which links strands B and F in facing β-sheets 
stabilizing the domains (Al-Lazikani et al., 1997). In particular, the conservation of the intramolecular  
S-S bonds in each domain throughout the amino acid sequence divergence, suggests that they play 
an important structural role (Lapanje and Dorrington, 1973). Moreover, an intermolecular S-S 
occurs at the C-terminus of the Cl. Specifically, this bond link the two Cls in a LC dimer, or the CL 
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with the Ch in the complete immunoglobulin (Nag et al., 2015). Remarkably, these S-S bonds takes 
place in stabilizing the overall homodimer quaternary assembly (Leitzgen et al., 1997). 
The VL fold consists in nine strands organized in two sheets one composed of four and the other 
one of five strands. Structurally, the five-stranded sheet is composed by strands C, C’,C’’, F and G. 
The other sheet consist in four strands known as A, B, E and D (Figure 1.3).  
Vl is directly involved in the interaction with antigens because of the presence of the three 
complementary determining regions (CDR1, CDR2 and CDR3) (Charles A Janeway et al., 2001). CDRs 
are known as hypervariable regions because of their sequence diversity, which provides specificity 
against antigens. Structurally, CDR1 connects strands B-C, CDR2 C’-C’’ and CDR3 F-G (Fischmann et 
al., 1991) (Figure 1.3). The definition and numbering of CDRs is a particular aspect that is well 
described in literature (e.g., North et al., 2011). In particular, the first attempt on the CDRs 
characterization was carried out in the mid 1990s by Chothia and coworkers, (Al-Lazikani et al., 
1997). Specifically, they used the term “canonical structures” for CDRs, on the base that these 
regions might only adopt few conformations and structure depending on length and sequence 
(Chothia et al., 1989). Recently, several studies by North and coworkers, are in contrast with this 
vision. In 2011 CDRs were classified depending on dihedral angle metric using an affinity-
propagation clustering algorithm (North et al., 2011; Adolf-Bryfogle et al., 2015). In particular, the 
study took in account more than 300 antibody structures previously deposited on the protein data 
bank (PDB) with the exclusion of those ones with low resolution and high B-factor. To date, this new 
model is the most used one to identify and numbering CDRs. 
The other domain, the Cl, is highly conserved among all the LC in terms of amino acid sequence 
(KARLSSON and PETERSON, 1972). Its fold consist two sheets as well as the Vl. The first is a three-
stranded sheet (strands C, F and G) and it is homologous to the VL five-stranded one but it misses 
strands C’ and C’’. The other one is a four-stranded sheet and present the same topology and 
organization of the VL (Fischmann et al., 1991)(Figure 1.3).  
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Figure 1.3: Schematic representation of the immunoglobulin light chain VL and CL motifs. 
 
The last part of the LC structure is composed by residues 111-114 which constitute a joining region 
linking together CL with VL and it is characterized by high flexibility (Bourne et al., 2002). 
 
1.1.2 Sequence variability 
 
The typical LCs high sequence variability arises from genetic and molecular reasons. Lambda locus 
(IGL) is located on chromosome 22q11.2 and consists of 73-74 IGLV (variable) genes, 7-11 IGLJ 
(joining) genes and 7-11 IGLC (constant) genes (HUGO Gene Nomenclature Committee, HGNC, 
Lefranc, 2001) (Figure 1.4). In particular, IGLV genes are divided in three segment: variable (V) and 
joining (J) (Adolf-Bryfogle et al., 2015). It is worth to know that LCs lack the so called diversity (D) 
segment. According to this chromosome subdivision each LC can be classified on their V-J (IGLV) and 
IGLC coding gene, leading to the concept of germline gene. Moreover, the IGLV genes are also sub-
grouped in ten families (from IGLV1 to IGLV10) (Jr et al., 1997). 
 
 
Figure 1.4: Simplified scheme of the LC locus on the chromosome 22. (Parham, 2014) 
 
Several studies focused on the definition and nomenclature of the whole repertoire of IGLV genes. 
In particular, two different works both published in 1995 analyzed the organization of the IGLV 
leading to two different nomenclature systems (Frippiat et al., 1995; Kawasaki et al., 1995). In 2001, 
the ImMunoGene Tics database published a study where they proposed the correspondence 
 11 
between the human IGLV nomenclatures and the one proposed by them (Table 1.1). In particular, 
they provided the IGLV previous genes according to gene functionality and number of alleles 
(Lefranc, 2001).  
From the molecular point of view, the sequence diversity is the result of the V(D)J recombination, a 
somatic non-homologous recombination indispensable for B-cells to become mature (González et 
al., 2007). In particular, this process occurs during the early differentiation of B-cells and generate 
the primary VL repertoire (González et al., 2007). Specifically, the first recombination event occurs 
at the variable k locus (IGKV) and if a functional rearrangement is not accomplished, the IGLV 
undergoes recombination (Gent and Burg, 2007). The process is regulated by the enzymatic 
machinery V(D)J recombinase (Mansilla-Soto and Cortes, 2003; Schatz and Ji, 2011) and it is 
controlled by the recombination signal sequences (RSS) flanking the V, D and J gene segments 
(Ramsden et al., 1994; Schatz and Ji, 2011) (Figure 1.5 A).  
V(D)J recombination starts when the V(D)J recombinase binds a RSS creating a single-strand nick 
between the coding segment (V, D or J) and the first nucleotide of the RSS (Schatz and Swanson, 
2011).  
 
Figure 1.5: (A) Schematic representation of the V-D-J recombination. (B) zoom-in into the hairpin 
formation (Little et al., 2015).  
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Table 1.1: Comparison between the human IGLV nomenclatures. (Lefranc, 2001) 
 
 
This reaction results in the formation at the 3’ of a reactive free hydroxyl group which is then 
positioned, by the V(D)J recombinase activity, to the phosphodiester bond of the other strand 
forming a hairpin on the coding segment (Curry et al., 2005; Schatz and Swanson, 2011) (Figure 1.5 
B). This process is known as recombination center formation (Agrawal and Schatz, 1997). 
The coding ends are then ligated in a process which leads to junctional diversity (Lewis, 1994). First, 
the endonuclease artemis (Helmink and Sleckman, 2012) opens the coding end hairpins in an “off-
center” way (Ma et al., 2005) giving rise to a shorter segment which needs to be elongated in order 
to be further joined. In particular, for this process palindromic (P) nucleotides are used. P 
nucleotides are complementary to the ones of the other segment and creates diversity among 
different recombination events (Lu et al., 2007). This crucial step is one of the two steps, which 
generate the high variability among LCs. Indeed, the addition of random nucleotides are reflected 
in the formation of virtually infinite amino acid combination after the translation process. In 
particular, this results in the amino-acid sequence diversity of the further synthetized proteins. 
Moreover, the diversity is generated by a second step of random amino acids addition. Indeed, the 
DNA ends elongated with P nucleotides are aligned and successively prolonged using non-templated 
(N) nucleotides (up to 20) (Gauss and Lieber, 1996). This second recombination event increases the 
probability to generate differences in LCs sequences. Remarkably, both the random addition of N 
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and P nucleotides could generate an off-frame DNA, which can lead to stop codons formation. The 
process ends with the ligation of the two DNA prolonged ends. 
 
1.2 Amyloidosis 
 
Amyloidosis indicates a group of protein-misfolding diseases characterized by the deposition of 
insoluble structured fibrils know as amyloid fibrils. Among such diseases, systemic amyloidoses are 
named the pathologies where the protein misfolds and aggregates elsewhere from where it is 
produced. Systemic amyloidosis can be grouped in several types: primary amyloidosis, usually with 
no evidence of preceding or coexisting disease, paraproteinemia, or plasma-cell dyscrasia; 
secondary amyloidosis, with evidence of coexisting previous chronic inflammatory or infectious 
conditions; hereditary amyloidosis which are associated to certain genotypes. 
On the contrary, localized amyloidosis are characterized by the presence of amyloid deposits in the 
same organ producing the protein involved (Hazenberg, 2013). This kind of amyloidoses is 
representative of the 11% of the total cases. In Figure 1.6 is reported the distribution of several 
types of amyloidosis.  
 
 
Figure 1.6: Distribution of several amyloidosis types among patients in 2012 (Amyloidosis Patient 
Information Site).  
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1.2.1 Amyloid fibrils and amyloidogenesis 
 
Amyloids are insoluble proteinaceous aggregates which acquire a cross ß-sheet enriched folded 
state (Rambaran and Serpell, 2008). They are found in several pathologies such as Alzheimer disease 
(AD), diabetes type II and spongiform encephalopathy. Amyloid fibrils structure is studied by several 
experimental techniques such as X-ray diffraction and electron transmission microscopy (TEM) 
(Figure 1.7 A). Through these experimental approaches it was possible to asses that amyloid fibrils 
have a common structure (Blake and Serpell, 1996). 
 
 
Figure 1.7: A. Amyloid fibrils TEM imaging; B. Amyloid fibril X-Ray diffraction pattern where two 
main reflections (4.7 Å and 10 Å) are highlighted. 
 
 Specifically, it consists in one or more filamentous subunits (Figure 1.9 B and C). Each subunit is 
composed of long polypeptides characterized by a cross-beta sheet quaternary structure, which are 
perpendicular oriented to the fibril axis (Sipe and Cohen, 2000) (Figure 1.9 C, D and E). In particular, 
this disposition allows the formation of hydrogen bonds increasing the overall stability of the fibril 
(Kirschner et al., 1986). The X-ray diffraction pattern present two reflections, the first is sharp and 
meridional: it is at 4.7 Å resolution (Figure 1.7 B) and it corresponds to the distance between the 
hydrogen-bonded ß-strands (Figure 1.9 D). The other reflection is strong and more diffuse on the 
fibril equator (Guijarro et al., 1998) (Figure 1.7 B) and accounts for the distance between facing β-
sheets (~10 Å) (Figure 1.9 D) (Rambaran and Serpell, 2008) .  
Amyloid fibrils can vary in terms of morphology presenting different width and pitch values. In 
particular, width values are generally in the order of ~10 nm while the periodic helical twisting 
(pitch) is highly variable (Figure 1.8) 
 15 
 
  
Figure 1.7: (A) Amyloid fibril picture by electron transmission microscopy, (B) schematic 
representation of the fibril, (C) Amyloid fibril structural organization, (D) Distance between the 
hydrogen-bonded ß-strands and (E) amyloid fibril axis (Fitzpatrick et al., 2013). 
 
 
 
 
 
Figure 1.8: Different amyloid fibrils morphologies. From 1 to 11 the pitch decreases (Fändrich et al., 
2009). 
 
Amyloid fibrils are the result of the aggregation process known as amyloidogenesis (or 
fibrillogenesis). This process starts by virtue of protein misfolding. In specific, in the case of 
Pitch 
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structured proteins, it occurs after an unfolding / partially unfolding event. Misfolding generates 
protein conformations distinct from the native state, facilitating to protein self-aggregation. 
Typically, in these aberrant conformations highly “sticky” hydrophobic patches usually buried in the 
protein core become exposed solvent and mediate monomer-monomer oligomerization (Moreno-
Gonzalez and Soto, 2011). 
Misfolding can occur because several non-physiologic conditions such as gene mutations, aberrant 
transcription process, failure of the chaperon machinery, incorrect post-translational modifications 
and high protein concentration (DeArmond and Prusiner, 1995; Duyckaerts et al., 2008; Matveyenko 
and Butler, 2006; Soto, 2001). Misfolded proteins form polymers of different size such as oligomers, 
protofibrils and fibrils (Caughey and Lansbury, 2003). Soluble oligomers are usually arranged in size 
usually from dimers to 24-mers (Glabe, 2006). To date, it is well accepted the subdivision of soluble 
oligomers in two principal categories: on-pathway and off-pathway. In particular, on-pathway 
oligomers are the ones leading to the assembly of mature amyloid fibrils; while off-pathway 
oligomers remain in equilibrium with the monomeric state of the protein (Lorenzen and Otzen, 
2014) (Figure 1.8).  
The kinetics of the amyloidogenetic process is usually described as a sigmoidal growth (Ferrone et 
al., 1985). Basically, it can be divided in three macro-events: lag phase, growth phase and final 
plateau (Arosio et al., 2015). During the lag phase the microscopic step known as primary nucleation 
occurs (Figure 1.10 A). This process is aimed to the production of nuclei suitable for amyloid growth, 
starting from soluble monomers. In particular, the nuclei are the species characterized by the 
highest free energy in the fibrillation process (Figure 1.9). 
.  
Figure 1.8: Amyloidogenesis. Schematic representation of the amyloid fibril formation with 
underlined the potential toxic species.  
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The second step is known as elongation and starts immediately after the primary nucleation, giving 
rise to the growth phase (Figure 1.10 B). It consists in the addition of monomers to the ends of 
existing aggregates promoting the growth of oligomers resulting in mature fibrils (Arosio et al., 
2015). The elongation rate is usually higher than the primary nucleation. Therefore, the fibrils 
appear almost immediately after the first nucleation, becoming a catalytic surface for the formation 
of secondary nuclei (Arosio et al., 2015). 
 
 
Figure 1.9: Schematic represented the different free energies among the species detectable during 
the fibrillation process. 
 
Indeed, during the growth phase the secondary nucleation occurs (Castello et al., 2017). This step is 
the process whereby nuclei formation is catalyzed by existing aggregates composed of the same 
protein (Figure 1.10 C). Therefore secondary nucleation totally depends from the presence of 
already formed aggregates, opposite to what happens for the primary nucleation (Törnquist et al., 
2018). Finally fibrils undergo spontaneous fragmentation, which increase the rate of fibril elongation 
(Figure 1.10 D).  
Over the years, the toxic potential of fibrillation intermediates has been characterized (Figure 1.8). 
To date, it is accepted that the elements exerting proteo-toxicity are different in different 
pathologies. For instance, in AD it was demonstrated that the toxicity is related to the amyloid 
deposits and the circulating soluble oligomer. Instead, in AL it has been observed that the soluble 
monomeric LCs are toxic in vivo (Diomede et al., 2017b) but, to date, there are no evidences of an 
oligomeric involvement. 
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Figure 1.10: (A) primary nucleation from monomers, (B) fibril elongation from existing aggregates, 
(C) secondary nucleation from monomers in solution, (D) fragmentation (Arosio et al., 2015). 
 
1.2.2 Light chain amyloidosis  
 
As already mentioned above, AL is the most common systemic amyloidosis and it counts for 
approximately the 70% of all patient suffering from a systemic amyloidosis (Palladini and Merlini, 
2016). This pathology is caused by a plasma cell clone that infiltrates into the BM which sets off a 
devastating multi-organ damage caused by LCs over-production (Merlini and Stone, 2006). 
Specifically the overexpression is clinically evaluated through the parameter serum free light chain 
(FLC). Indeed, in pathology the FLC k/ λ ratio is altered (~0.26 mg/L) compared to the normal one 
(1.85 mg/L). Specifically, the over-produced LCs aggregate and deposit in tissue as amyloid fibers 
(Merlini, 2017). All organs, with the exception of the central nervous system, can be compromised 
(Milani et al., 2018) with heart being the most affected one (Milani et al., 2018) (Figure 1.11). It is 
also worth to know that AL is an aging pathology: indeed, the LCs overexpression leads to the 
deposit formation over the years (Picken, 2007). 
 
Figure 1.11: Organs involvement in AL. (Merlini, 2017)  
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The AL etiology is not fully understood but to date several progresses in understanding the biology 
of plasma cells helped unraveled the molecular pathological mechanisms. In particular, it has been 
observed that the plasma cell clone is often characterized by several chromosomal abnormalities 
(Milani et al., 2018). The most representative one is the translocation t(11;14) which is typical of the 
50% of patients and due to cyclin D1. Another alteration is the gain of 1q21 which is observed in less 
than 20% of cases (Bochtler et al., 2008). Interestingly, the phenotypic and copy number alteration 
of the plasma cell clone in AL is similar to those ones found in MM. However, in AL, the gene 
expression profile is comparable to the one of normal plasma cells (Paiva et al., 2016). Remarkably, 
through a genome wide association study (GWAS) it was observed that AL and MM present shared 
genetic susceptibility. In particular, it was underlined the preferential role of cyclin D1 in driver AL 
rather than MM. Anyway the most relevant property of such cells is the ability to overproduce LCs, 
which leads to high soluble protein concentration in the blood flow. In particular, this scenario 
generates extremely favorable conditions for protein aggregation. 
As already explained, all organs can be affected by AL but the tropism remains to be elucidated. In 
particular, a study published in 2016 reveals the tendency of an organ to be affected, depending on 
the IGLV clone (Weiss et al., 2016). Other studies (e.g., Abraham et al., 2003; Perfetti et al., 2004) 
had previously identified IGLV2-14, IGLV6-57, and IGLV3-1 germline genes as the ones contributing 
in encoding the majority of λ LCs. From these observations, in 2017 It was found that the germline 
gene IGLV6-57 is commonly found in AL and it is associated with renal involvement, but remains 
extremely rare in normal B-cells (Kourelis et al., 2017). Moreover, the germline gene IGLV1-44 was 
found to be linked to predominant cardiac involvement (Perfetti et al., 2012).  
Heart failure is typically caused by the alteration of the cell metabolism and oxidative equilibrium 
and the contraction disfunction. First, the LCs interaction with proteins involved in vitality and 
metabolism leads to aberrant oxidative balance (Lavatelli et al., 2015) suggesting that LCs may be 
internalized (Grogan et al., 2017). Moreover, the contraction mechanics are disrupted because of 
the infiltration of amyloid deposits into the myocardium, which interfere with the cell integrity and 
cell-cell coupling (Mohty et al., 2013) (Figure 1.12). Specifically, the contraction dysfunction 
mechanisms are linked to the non-canonical p38α MAPK pathway (Shi et al., 2010) and this 
molecular signaling promotes the expression of the cardiac stress hormone brain natriuretic peptide 
(BNP) (Grogan et al., 2017). 
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Figure 1.12: Schematic representation of the heart damage due to the presence of amyloid deposits. 
 
BNP secretion is caused by an excessive stretching of the heart walls, which lead to an increase in 
the ventricular blood volume. It is synthetized as a 134-amino-acids in the pre-pro-hormonal form 
(preproBNP). This molecule is then converted in the prohormone (proBNP) by a cleavage at its N-
terminal signal peptide. Successively, NT-proBNP (the proBNP N-terminal fragment) and in the 
biological active BNP are produced by a proBNP cleavage between R102 and R103 (Figure 1.13) 
(Schellenberger et al., 2006). Along this line, BNP and in particular NT-proBNP were extensively 
characterized (Merlini et al., 2016) and to date, it is routinely used as clinical biomarkers for AL 
severity of heart involvement. In specific, values of BNP <100 pg/mL and NT-proBNP <300 pg/mL 
can exclude a cardiac involvement. It is worth to underline that the biological BNP response is also 
linked to the presence of monomeric LCs, suggesting that they may drive proteo-toxic mechanisms 
(Merlini et al., 2016) (see results 1.2.2.3). 
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Figure 1.13: (A) BNP biosynthesis.(B) detailed on the proBNP cleavage in NT-proBNP and BNP  
(Jarolim, 2006) 
 
1.2.2.1 Epidemiology, symptoms, diagnosis and therapy 
 
Epidemiology. AL has an incidence of ~10 per million person-years (Falk et al., 1997). Patients are 
preferential male with a ratio male-female of 3:2 and a mean age at diagnosis of 63 (Baker and Rice, 
2012; Quock et al., 2017). In AL the LC λ isotype is the most abundant one found in patients with 
the k/λ ratio < 0.26 in terms of FLC (Rajkumar, 2016) although in healthy individuals is the reverse 
(Jones, 1848). However, it must be noted that the pathology could also be caused by the 
overproduction of k LCs. In those patients, the k/λ ratio is different and higher with respect the 
physiological one (~ 0.6) (Katzmann et al., 2002). 
Symptoms. Symptoms may be very heterogeneous and in the early phases of the pathology can be 
minor and similar to the ones of other pathologies. By time the disease is becoming progressively 
more severe on the organ(s) affected. However, there is a common set of symptoms that may have 
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been present for some time before diagnosis, such as chronic fatigue and weakness (Amyloidosis 
foundation). The heart involvement is the most life threatening (see introduction 1.2.2).  
 
 
Figure 1.14: Histological sections showing the amyloids infiltrates (Falk et al., 1997) 
 
In particular, deposits lead to the expansion of the extracellular space resulting in the stiffening of 
cardiac tissue without producing a compensatory dilatation (Figure 1.14). This process results in a 
restrictive pathophysiology known as “stiff-heart syndrome” (Falk et al., 1997). Specifically, this 
condition leads the 25-33% of patients to heart failure within six months (Dispenzieri et al., 2004). 
Another cardiac symptom is the arrhythmia, which is present when amyloids affect the electrical 
heart system. One very typical condition for AL patients is proteinuria, which is a very useful for the 
diagnosis. The urine-derived LCs are known as Bence-Jones (BJ) LCs (Jones, 1848). 
Diagnosis. The AL diagnosis is usually done in several ways but the main critical step is the clinical 
suspicion (e.g., altered BNP and pro-BNP values). The 90% of the cases are identified through the 
combination of serum protein electrophoresis with immunofixation electrophoresis (SPEP/IFE) and 
a 24-hours urine collection monitored by electrophoresis. In 2005, the addiction of the 
quantification of the FLC increased efficiency of diagnosis since this clinical parameter is abnormal 
in 99% patients (Gertz et al., 2005). Although these tests are effective tools for the AL diagnosis, 
tissue biopsy confirmation is required: in particular, abdominal fat pad aspiration (sensitivity around 
85%), rectal biopsy (75-85%), and bone marrow biopsy (around 50%) (van Gameren et al., 2006; 
Schatz and Swanson, 2011). 
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Figure 1.15: AL diagnosis criteria (Syed A. Abutalib and Anita D’Souza). 
 
Therapy. AL therapy is a challenge for physicians since both the bone marrow disorder and the 
involved organ disfunctions have to be taken in account (Milani et al., 2018). The specific organ 
treatment should be referred to specialized centers. 
The amyloid clone is treated with chemotherapy aimed to its neutralization (Muchtar et al., 2017). 
The Amyloidosis foundation reports the most used drugs to be Melphalan, Cyclophosphamide and 
Bendamustine. In patients with a severe cardiac involvement it is not possible the use high 
chemotherapeutical agents doses since their heart do not withstand the therapy (Merlini et al., 
2016). However to date, the ones above are the election therapy for high-risk patients. Low-risk 
patients, who represent the 15% of the cases, are good candidates for autologous stem cell 
transplantation (ASCT). This approach is associated with a higher risk of early mortality with respect 
its use on MM patients. However, the patients selection criteria nowadays are improved leading to 
a decrease in the risk of mortality over time (D’Souza et al., 2015).  
Immunomodulatory drugs (ID) and proteasome inhibitors are the other drug-classes used in AL 
treatment. However, the choice of a given drug depends on the organs involved. For instance, the 
proteasome inhibitor carfilzomib leads to a hematological response of 63% but it exerts cardiac 
toxicity hence it not suitable for patients with cardiac involvement. Among the ID, ixazomib is one 
of the most promising one. This drug is highly active in pre-treated patients therefore it seems 
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suitable for drugs combinations. For these reasons ixazomib is now in a randomized phase III trial in 
relapsed / refractory patients (Milani et al., 2018). 
 
1.2.3 Biochemical and structural characterization of the AL deposition.  
 
The biophysical mechanisms of proteotoxic LCs in AL amyloidosis remains to be fully elucidated. 
Indeed, to date, the comprehension of the molecular pathophysiology misses some crucial aspects. 
First, it is not known why only a subset of LCs aggregate. To address this important point, several 
reports considered the aminoacidic sequence (e.g., Dwulet et al., 1985; Hurle et al., 1994). In 
specific, in literature is indicated that it may have a role in the aggregation propensity but, to date, 
a direct correlation between sequence and amyloidogenicity has not yet been assessed. Another 
important point that needs to be highlighted regards the species that aggregates. Indeed, although 
several reports identified VL as being the main constituent of fibrils, amyloid can also comprise CL 
and FL LCs In other words there is no consensus on which species aggregate and which exert the 
tissue toxicity. In this regard, a recent study by Marin-Argany et al., suggested that LC fragments are 
toxic, even at low concentrations. They can aggregate and recruit soluble proteins, resulting in 
elongation of amyloid fibrils and cellular toxicity (Marin-Argany et al., 2016). 
All these opened-questions underline the high molecular and biophysical complexity of the LCs 
aggregation propensity. Herein, it will be discussed the studies conducted on VL and on the FL LCs. 
 
1.2.3.1 VL structural and biophysical studies 
 
As mentioned above, for several reasons VL has been considered for long time as the main 
component of the amyloid deposits (Buxbaum, 1992), thus, the majority of the structural and 
biophysical studies focus on VL domains and their amyloid propensity. First, it was established that 
a low VL thermodynamic stability is associated with an increased propensity to form amyloid fibrils 
(Baden et al., 2008a, 2008b; Wall et al., 1999). This properties has been correlated to the production 
of partially unfolded states which may necessary start the aggregation reaction (Wetzel, 1997). 
Indeed, when they populate amyloidogenic experimental conditions, the fibrillogenesis process is 
accelerated (e.g., Chiti and Dobson, 2006). This evidence has been further confirmed by other 
studies. Importantly, it was noticed that unfolded or native LCs conformations do not lead to fibril 
formation. Indeed, variants with very high or very low thermal stability that is they are in fully folded 
or totally unfolded states do not produce fibrils (M. Blancas-Mejia et al., 2018). Moreover, Khurana 
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and coworkers reported that native-like intermediates, generated at relatively low pH values (4.0 - 
6.0), resulted to be prone to generate amorphous aggregates. While, relatively unfolded but 
compact intermediates, observed at pH values below 3.0, are prone to generate amyloid fibrils.  
These studies has been also structurally supported. Indeed, Eisenberg and coworkers proposed 
three models for the VL fibrillogenesis based on the VL-VL interface and the oligomerization state 
(Figure 1.16). In particular, these models were named: canonical dimer model, non-canonical dimer 
model and monomer model.  
 
 
 
Figure 1.16: Vl-based fibrillogenesis model depending on the VL-VL interface (Eisenberg et al., 2014) 
 
The first one assumes that the amyloid formation is reversible. In the second one the VL-VL dimers 
quaternary structure is altered but maintains the hydrophobic environment of the cavity in 
correspondence of the VL-VL interface (Brumshtein et al., 2014). While, the third one considers 
soluble monomeric Vls. Interestingly, they highlighted that VL-VL dimer, especially the non-
canonical one, may be partially unfolded and therefore destabilizing mutations would lead the VL 
to assume an amyloid-prone tertiary structure while stabilizing mutations would inhibit the 
fibrillogenesis (Brumshtein et al., 2014; Edmundson et al., 1976). Then, to stress the role of partially 
unfolded states, it has to be considered that amyloid fibrils in vitro can also been produced by 
monomeric Vl. Indeed, in Brumshtein et al., it is reported that soluble VL-VL dimers dissociate in 
monomers which partially unfold leading to thermodynamic destabilization which results in amyloid 
fibrils formation (Qin et al., 2007). Taken together, these data support the hypothesis that the 
ordered self-assembly of partially folded species are crucial as trigger of amyloidogenesis becoming 
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the soluble precursors of fibrils (e.g., Chiti and Dobson, 2006; Ramirez-Alvarado et al., 2000 Khurana 
et al., 2001).  
These studies are particularly interesting, and stressed by other reports (e.g., Alvarado, 2018), 
because the stabilization of these partially folded species may results in the identification of 
molecules with anti-aggregation properties. Indeed, on this rationale, Eisenberg and colleagues 
identified ligands that inhibit amyloid formation in vitro by stabilizing the VL-VL dimer (Brumshtein 
et al. 2015).  
Another interesting aspect that was considered over the years is the role of sequence variability. 
Indeed, VL is the LC region that accumulates somatic hypermutations. This fact is stressed by the 
presence of CDRs, that present the highest sequence variability in order to achieve high-affinity 
antigen binding. 
In 1985 a detailed primary structure analysis on a big number of VL sequences revealed that two 
residues insertions (positions 68 and 69) may be linked with LC aggregation propensity (Dwulet et 
al., 1985). Moreover, In 1994, Wetzel and coworkers reported that in amyloidogenic VL in specific 
positions given amino acids are found at markedly high frequency (Hurle et al., 1994). More 
recently, it has been reported that the amino-acid sequence has a structural role in the VL-VL 
interface. Indeed, It was underlined that LCs populate at least 3 different dimer interfaces in a 
dynamic equilibrium that depends on the specific amino acid substitutions in the dimer interface 
residues (M. Blancas-Mejia et al., 2018). 
Finally, in literature was inspected the role of co-factors in facilitating protein aggregation. For 
instance, glycosaminoglycans (GAGs), which are negatively charged, unbranched, long hetero-
polysaccharides (M. Blancas-Mejia et al., 2018) were found associated to amyloid fibrils (Ramirez-
Alvarado, 2012). In particular, their charge is an important factor which contributes to accelerate 
amyloid formation in vitro (Martin and Ramirez-Alvarado, 2011).  
 
1.2.3.2 FL LCs: biochemical studies 
As mentioned above, VL plays a crucial role in amyloid formation through its intrinsic instability and 
its consequent tendency to form partially unfolded states. However, it must be considered that 
isolated soluble Vls are not detectable in vivo (Lavatelli et al., 2011) and the relevance of studying 
VL domains in the context of the disease is under debate.  
Moreover, over the years, it has been demonstrated that not only VL populates amyloid deposits. 
Indeed, mass spectrometry analysis of biopsy tissues reported the presence of the FL LC in patients’ 
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samples (Lavatelli et al., 2008). Moreover, FL LCs exert cardiotoxicity also without the production of 
fibrils (e.g., Diomede et al., 2014; Malpasso et al., 2013), especially in the case of AL with cardiac 
involvement. Remarkably, Merlini and coworkers underlined a solid correlation between the blood 
concentration of soluble LCs and the severity of heart symptoms (Milani et al., 2018). Indeed, toxic 
LCs injected in vivo in the heart of wt mice lead to end-diastolic pressure (Palladini et al., 2010). 
Recently Diomede and co-workers established a model to recapitulate LC toxicity in vivo: C. elegans 
fed by solution of LCs shows a impairment in the larynx pumping rate in presence of cardiotoxic LCs 
and not with non-cardiotoxic or M LCs (ref). This well describes what seen in patients. Moreover, 
they also identified the role of Cu2+ in enhancing the FL LCs toxicity by altering the RED-OX balance 
(Diomede et al., 2017b). In details, it was observed that the LCs and Cu2+ co-administration results 
in a higher toxic effect rather than the LCs alone, opening new routes for the understanding of LCs 
toxic mechanisms. 
Even though the identification of molecular species which plays the toxicity trigger remains a crucial 
issue to be elucidated, all these observations strongly highlight the importance of characterizing FL 
LCs being the relevant pathologic molecular species.  
 
Biophysical characterization of FL LCs aggregation propensity. Considering the overall stability of 
Vl, CL or FL LC, CL is the one characterized to be the highest thermal stable and the VL the less one 
(Klimtchuk et al., 2010). Consequently, in a FL LC, CL plays the crucial role to stabilize VL (and VL to 
destabilize CL through intermolecular interactions. In particular, Klimtchuk et al., underlines that 
the VL lower thermodynamic stability correlates with the lower kinetic stability of the FL protein. 
This implies that, in FL LCs, increasing the population of the unfolded VL region destabilizes the CL 
region, possibly via the direct interactions between these partially unfolded regions facilitated by 
their linkage via the joining region. These interdomain interactions result in a FL LC conformational 
shift toward partially unfolded states that are prone to irreversible aggregation (ref?).  
The role of CL domains in stabilizing VL and the whole LC molecules is also stressed by Kelly and 
coworkers. They observed that amyloidogenic FL LCs unfolds faster than non-amyloidogenic LCs 
ones. However, they established that this instability is not sufficient by itself to cause amyloid 
formation indeed they did not observe fibril formation from FL LCs. Thus it has been hypothesized 
that when covalently bound to VL the CL domain prevents aggregation, through a mechanism that 
remains to be determined (Morgan and Kelly, 2016). 
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The lower VL overall stability has also been observed in other studies (e.g., Blancas-Mejía et al., 
2017a). In particular, this domain resulted not able to be completely refolded. Indeed, Blancas-Mejía 
et al. noted that the refolding of FL LCs consists in 2-step transitions while the unfolding present a 
3-step unfolding transition. These results suggested that one of the two domains does not 
completely refold (possibly the Vl) giving rise to a strong kinetic control of the LCs unfolding process. 
Together, these findings revealed that the FL protein is likely more prone to form amyloid fibrils 
through partial unfolded states dependently to the kinetic barrier which counterbalance the 
aggregation propensity. Indeed, in this model the rate of FL LC aggregation is dependent to the 
height of this kinetic barrier, which is partially regulated by the VL thermodynamic stability. The role 
of kinetic stability was also considered by Kelly and coworkers: this parameter was shown to 
influence the FL LCs propensity to form amyloid (Morgan and Kelly, 2016). Their findings underlined 
that amyloidogenic FL LCs are kinetically unstable in comparison to the non-amyloidogenic ones. In 
addition, they also underlined endoproteolytic release of fragments from the FL LC as another 
important aspect in aggregation. Indeed, they observed that amyloidogenic low kinetically stable FL 
LCs can be readily cleaved into their component domains by proteases, releasing the Vl, which is, in 
isolation, highly amyloidogenic.  
In summary, the above observations stress the relevance of a research project that by biophysical 
and structural approaches aims to more systematically characterize the specific properties of 
amyloidogenic and toxic LCs. Given the their relevance in vivo, FL proteins should be used rather 
than isolated VL and in order to take in account the exceptional sequence variability which 
characterizes this disease several sequence diverse LCs should be taken in account. 
By identifying the molecular bases of LC aggregation propensity and toxicity, the long-term aim of 
such project will be to set the bases for designing strategy to control and ultimately abrogate LC 
amyloid aggregation.   
 29 
 
2 Results 
 
This is a comprehensive study aimed to investigate possible molecular mechanisms driving 
cardiotoxic LCs to protein aggregation and in vivo toxicity. Herein, we considered two interesting 
points: i) the LCs biophysics and structure and ii) the effect of copper (Cu2+) on cardiotoxic LCs. In 
order to reach this aim, we focused our studies on several traits by analyzing fold stability, 
hydrophobicity, protein flexibility, molecular interactions and 3D structures, all properties, which 
can play a role in protein misfolding. 
 
2.1 Evaluation of cardiotoxic LCs discrepancy to non-cardiotoxic: study set up 
 
The cardiotoxic LCs biophysics and structures have been evaluated in comparison with the non-
cardiotoxic LCs. In particular, we analyzed the possible differences, which may account for different 
aggregation propensity. To this intent, given the high sequence variability, we considered a pool of 
thirteen proteins divided in two sets: one set is composed of eight LCs isolated from AL patients 
with severe cardiac involvement and they are referred as ‘H’ LCs (H3, H6, H7, H9, H10, H15, H16 and 
H18). The other set (‘M’ LCs) were non-toxic and isolated from patients suffering of multiple 
myeloma (MM) (M2, M7, M8, M9 and M10). In specific, as reported in the introduction, H LCs are 
overexpressed in blood resulting in organ toxicity and amyloid deposition. On the contrary, in MM 
patients non-toxic LCs are overexpressed but no toxicity and no amyloid formation occur, making 
M LCs a proper control. Anyway, MM patients producing these proteins were carefully screened 
and monitored over the years, to rule out the presence of amyloid deposits. 
In details, our experimental activities were performed on the native LCs since it is the starting 
species leading to amyloidogenicity. Moreover, only FL LCs were considered because their 
concentration correlates with the severity of heart symptoms. It should be noted that a pool 
composed of a such high number of protein represents an innovation in the characterization of AL 
proteins. Moreover, all the proteins belong to different plasma-cell families in order to increase the 
sequence variability (Table 2.1) and to avoid to obtain results specific for given LC families. This pool, 
large in biochemical terms, allows considering our data representative of general LC traits.  
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The proteins were purified from two different sources: i) patients’ urine (BJ: H9, H10, H15, H16, H18, 
M2, M7, M8, M9, M10) ii) Escherichia coli (recombinant, rec: H3, H6, H7, H9, M7, M8, M9) (Table 
2.1).  
Table 2.1: LCs ID; Source of purification (BJ or recombinant); Germline gene and family on 
brackets. 
 
 
LC ID REC/BJ Germline 
H3 REC 1c  (IGLV1-44) 
H6 REC 1b  (IGLV1-51) 
H7 REC 1b  (IGLV1-51) 
H9 REC/BJ 2c  (IGLV2-8) 
H10 BJ 1a  (IGLV1-36) 
H15 BJ 6a  (IGLV6-57) 
H16 BJ 2a2  (IGLV2-14) 
H18 BJ 3l  (IGLV3-19) 
M2 BJ 2b2  (IGLV2-23) 
M7 BJ 3l  (IGLV3-19) 
M8 REC/BJ 2b2  (IGLV2-23) 
M9 REC/BJ 2b2  (IGLV2-23) 
M10 BJ 2a2  (IGLV2-14) 
 
 
2.1.1 Sequence analysis 
 
The LCs amino acidic sequences significantly vary because of their genetic recombination. 
Specifically, the sequence variability allows each LC to interact with a specific antigen (Ag). Indeed, 
the VL sequence identity referred to the LCs pool here presented is 25% (as determined by MUltiple 
Sequence Comparison by Log- Expectation, MUSCLE) (Edgar, Robert C., 2004). As expected, the 
highest degree of variation was found in the three CDRs regions where there is no sequence 
conservation. On the contrary, CL sequence is shown as highly conserved among all the presented 
LCs (identity 95%, MUSCLE alignment) with the exception of six conservative mutations which do 
not alter the overall fold (Figure 2.1). 
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Figure 2.1: Multialinegment of the thirteen LCs: 8 H LCs (H3, H6, H7, H9, H10, H15, H16, H18) AND 
5 M LCs (M2, M7, M8, M9, M10). ∇:	End of the Vl. 
 
2.1.2 Purification protocol and optimization 
 
With the aim to increase the amount of protein suitable for our studies, we set expression and 
purification protocols as recombinant proteins for H3, H6, H7, H9, M7, M8 and M9. Indeed, BJ LCs 
(herein: H9, H10, H15, H16, H18 M2, M7, M8 and M9 purified at the Amyloidosis Research and 
Treatment Center, San Matteo hospital, Pavia) can be obtained in small amount and for limited 
amount of time. 
The LCs genes were cloned in the PCR-TOPO-2.0 cloning plasmid and successively in the pASK-IBA33 
plus (H3, H6, H7 and M9, previously cloned by collaborators in Pavia) or pET21b (H9, M7 and M8) 
for the E. coli expression. LCs cloned in pASK-IBA33 plus were expressed and purified according to 
previously published protocols (Rognoni et al., 2013). In this case, proteins were produced using the 
BL21 E. coli strain. The overexpression was obtain by the induction with 0.43 µM 
anhydrotetracycline for four hours at 37 °C. 
On the contrary, the expression conditions for the LCs cloned in pET21b were set up from scratch. 
First, a multi expression test was performed. Different E. coli strains (BL21, Rosetta, Rosetta-gami, 
origami and shuffle) were tested, with the BL21 resulting the most efficient one. We used isopropyl-
β-D-1-tiogalattopiranoside (IPTG) as protein overexpression induction system. In particular, the best 
induction conditions found were 0.5 mM IPTG for four hours at 37°C.  
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After the expression, LCs were always detected as inclusion bodies in the insoluble E. coli fraction. 
We refolded LCs by dilution in presence of oxidized and reduced glutathione according to their 
isoelectric point (pI) since the first chromatographic step consisted in an ionic exchange. Indeed, the 
pI must be considered for the choice between anionic or cationic exchange. 
Specifically, H3, H7, H9, M7 (pI ~6.0) and M9 (pI 6.8) were purified by an anionic exchange 
chromatography in Tris 10mM pH 8.0, while H6 and M8 (pI ~8.0) by a cationic one in 10mM sodium 
acetate pH 6.0. In each case LCs eluted at a salt concentration in a range between 160 mM and 240 
mM sodium chloride (NaCl). The second chromatographic step consisted in a size exclusion 
chromatography (SEC). This step was carried out in order to: i) eliminate aggregated protein and ii) 
lower NaCl concentration. LCs eluted in 50 mM sodium phosphate (NaPi) pH 7.4 or 10 mM tris pH 
7.4 depending on the requirement of the different techniques. Interestingly, SEC profiles for same 
LCs were not always comparable both in terms of elution profiles and of yield. First, the differences 
in the elution profile are probably due to a low refolding efficiency. Indeed, protein refolding is a 
complicated process difficult to be reproduced. In particular, for instance it is responsible of the 
right secondary structures acquisition or the right disulfide bridges (S-S) formation. Moreover, the 
different yields could be accounted for the refolding efficiency too, but they also depend on the 
different starting material amount used for different purifications. 
 
 
 
2.2 Biophysical characterization 
 
The LCs pull was biophysical characterized with the aim to screen different properties of their native 
state. Herein, we considered fold stability, hydrophobicity and flexibility/dynamics. 
 
2.2.1 Fold stability  
 
With the objective to assess protein stability samples were tested using Circular Dichroism (CD) 
spectroscopy and fluorescence.  
First, LCs were analyzed by CD in Far-UV region (195-280 nm). This technique provides information 
about the secondary structures content. LCs spectra were collected and compared, showing that 
LCs fold in solution is comparable (Oberti et al., Figure S1). In particular, the overall shape is 
conserved and moreover each spectrum present a minimum at 218 nm, which is specific for protein 
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enriched in β structures. All spectra are highly similar with the exception of H7, which displays a 
spectrum not comparable with any other proteins. However, from other experiments (fold stability 
and structure determination), this LC resulted to be in its properly folded native state. Therefore 
the reasons why it presents a different CD spectrum remains unclear. From these data we assessed 
LCs fold in solution to be highly similar and no specific features to be correlated with aggregation 
propensity could be identified.  
Successively, the samples melting temperatures (Tm) were assessed by monitoring the CD signal at 
202 nm, while the temperature was increased up to 80 °C (Figure 2.2 A). Our data showed H LCs to 
be less thermal stable than M LCs (Table 2.2). In particular, the averaged H LCs Tm values (53.6 ± 1.5 
°C) is lower than the average of the ones measured for M LCs (62.8 ± 7.1 °C) (Figure 2.12). 
Specifically, H LCs Tm values cover a range between 52.9°C to 55.6°C with H6 and H15 being the 
least and the most stable, respectively. Instead, M LCs Tms range between 54.7 °C and 72.6 °C with 
M7 being the least stable and M8 the most one. Among the highly stable M LCs, M7 and M10 
represented two exceptions since their Tm values (54.7°C and 58.0 °C respectively) were similar to 
the ones measured for H LCs. From these experiments we concluded that H LCs typically possess a 
lower fold stability than M LCs even though the correlation is not 100%.  
LCs have also been evaluated by Near-UV CD (250-350 nm). This technique provides information on 
protein tertiary structure by monitoring at the circular polarized light absorption of the aromatic 
amino acids. As our findings report, the majority of the LCs tested (H6, H9, H10, H15, H16, M2, H18, 
M2, M7, M8 and M10) present comparable spectra underlying that the overall tertiary structure is 
conserved (Oberti et al., Figure S1). However, since this technique considers aromatic amino acids, 
it provides only information in their local environment. Indeed H3, H7 and M9 could not be 
compared due to differences in their aromatic amino acids chemical environment.  
We also measured the Tms by using Near-UV CD. As reported in Table 2.2 H3, H7, H9, H10, H16, 
H18, M7, and M9 thermal unfolding monitored by near-UV analyses confirmed the Tm measured 
by the Far-UV CD. Anyway, the concentration required for this technique (1mg/mL) may lead to 
protein aggregation (Figure 2.2 B). This prevented the Tm assessment for H6, H15, M2, and M10. 
From these analyses we concluded that the loss of the secondary and the tertiary structure are 
simultaneous processes, indicating that LC dimers unfold through a cooperative process. Moreover, 
we assessed that although it seems to have a role, the aggregation propensity cannot be interpreted 
by the fold stability itself. 
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Figure 2.2: CD thermal ramps of H and M LCs: Far-UV (A) and Near-UV (B). Labels report the LC ID 
and the family where they belong.  
 
 
2.2.2 Surface Hydrophobicity and stability  
 
Aiming to investigate on LCs hydrophobicity we carried out both computational and experimental 
methods (fluorescence). 
First, the hydrophobic amino acids content was computationally measured revealing that it is very 
comparable between H and M LCs sequences (~23%). Then, surface hydrophobicity was 
experimentally evaluated monitoring 8-anilinonaphthalene-1-sulfonic acid (ANS) fluorescence. This 
technique provides information about hydrophobicity since ANS fluorescence increases when the 
compound interacts with to hydrophobic regions. We titrated LCs using ANS up to 100 µM. 
Remarkably, we found the titration spectra to be highly comparable among all the LCs (Figure 2.3). 
In particular, the increment in ANS fluorescence is not significant and therefore these data indicate 
that none of the LCs display hydrophobic patches on their surfaces. 
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Figure 2.3: Representative ANS titration spectra. All the LCs presented the same spectra’ shape and 
therefore here only H18 and M9 are shown. Labels report ANS concentration. 
 
Then, temperature ramps were recorded in presence of 100 µM ANS for each LC (Figure 2.4). This 
allows monitoring protein unfolding by the increase in ANS fluorescence upon the exposure of the 
hydrophobic residues present in the protein core. These findings confirmed our assessments on 
protein stability. In particular, H LCs tend to be less stable than M LCs and therefore they can quickly 
expose their hydrophobic core. It must be noted that the unfolding process presented a single 
denaturation event suggesting that the two domains do not present independent unfolding events. 
This fact agrees with our results obtained by CD although for some LCs (H3, H6, H7, M9) a two-step 
unfolding was observed. However, in these cases, we assessed that the exposure of the hydrophobic 
core corresponds to the second unfolding step recorded by CD. Therefore, further experiments will 
be performed to clarify the presence of the other step. 
Interestingly, the onset of ANS signal correlates with the Tm obtained by CD rather the inflection 
point of the curve. This fact suggested that the hydrophobic core is exposed only at an advanced 
state of unfolding leading to an overestimation in ANS thermal unfolding. 
Taken together, these data revealed that hydrophobicity is highly similar in all tested LCs. Therefore, 
it could not be correlated to protein aggregation. 
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Figure 2.4: Thermal stability assessed monitoring ANS fluorescence of H and M LCs. Labels report 
the LC ID and the family where they belong. 
 
Table 2.2: LCs Tm recorded in the far-UV and in the near-UV regions for each LC; Temperature 
values corresponding to the ANS fluorescence onset for each LC. 
 
LC ID Tm Far-UV (°C) Tm Near-UV (°C) Onset ANS  fluorescence (°C) 
H3 54.4 53.1 54.8 
H6 52.9 - 55.3 
H7 54.7 56.2 54.8 
H9 52.9 54.0 55.8 
H10 54.9 54.3 58.3 
H15 55.6 - 54.7 
H16 51.3 51.9 54.5 
H18 52.4 51.1 51.5 
M2 61.5 - 63.9 
M7 54.7 55.3 58.8 
M8 72.6 - 73.5 
M9 67.0 67.7 62.8 
M10 58.0 - 56.1 
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2.2.3 Protein flexibility  
 
Then, protein flexibility was considered by limited proteolysis analyses. This molecular property can 
be studied through this approach since it is correlated to the kinetics of proteolysis. In specific, highly 
flexible proteins are characterized by fast kinetics. 
First, we carried out experiments with trypsin, a protease with cleavage specificity in 
correspondence of Arg and Lys residues. Our findings showed that the kinetics of proteolysis is faster 
in the case of H LCs as reported in Figure 2.5 and 2.6. The degree of flexibility was measured, in 
function of time, as the uncleaved protein fraction evaluated by densitometry after SDS-PAGE 
analyses. In particular, 50% of the total M LCs amount was still uncleaved after 3 hours of trypsin 
treatment while H LCs uncleaved fraction was lower than 50%. We divided H LCs in two subgroups: 
the one composed by H10, H15, and H18 with an uncleaved protein fraction from 20 to 50 % and 
the other one composed by H3, H6, H9, H7, and H16 with a final amount of uncleaved protein lower 
than 20%.  
These experiments were conducted in presence of a sub-denaturing urea concentration in order to 
obtain a sufficiently fast kinetics of proteolysis to be studied. 
It is worth noting that LCs were all characterized by different proteolytic patterns (Figure 2.5). In no 
one of the cases was possible to observe the presence over time of protease-resistant fragments. 
In particular, this feature may be correlated to LCs different amount of trypsin cleavage sites. 
Indeed, using specific proteases, the presence of recognized sites and their abundance in the protein 
sequence must be considered. In order to address this issue, computational analyses using Peptide 
Cutter were performed (ExPASy Peptide-Cutter tool: Gasteiger et al., 2005). Specifically, we 
observed a comparable number of cleavage sites between H and M LCs with some M LCs presenting 
more than H LCs. Therefore, we concluded that the faster kinetics of proteolysis is not correlated 
with the number of trypsin cleavage sites and therefore it may be depended on intrinsic properties 
of the LCs native state.  
Taken together, these data highlighted H LCs to be more flexible compared to the M one. 
Remarkably, these findings are consistent with what previously reported in literature. For instance, 
Morgan et al. reported three amyloidogenic LCs presenting a fast kinetics of proteolysis due to 
kinetic instability of the native state. Indeed, higher flexibility increases the probability to experience 
an unstable/less stable conformation characterized by high aggregation propensity. It is also 
remarkable that fold stability and kinetics of proteolysis do not necessarily correlate. For example, 
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M7 displayed the lowest Tm among the M LCs, but also very slow proteolysis kinetics; while H3 
showed relatively high Tm, within the H group, but it is quickly proteolysed by trypsin.  
 
 
 
 
 
Figure 2.5: SDS-PAGE monitoring the limited proteolysis of H and M LCs by trypsin. The first 
sample was taken one minute after trypsin addition (1) and then at 10, 20, 30, 60, 90, 120, 150 
and 180min of reaction time. LC is a standard amount of pure LC without trypsin (Tr). MM 
indicates molecular markers their mass is expressed in kDa.  
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Figure 2.6: Limited proteolysis kinetics of H and M LCs.  
 
To further confirm the results obtained using trypsin, limited proteolysis experiments were 
performed also using proteinase K, an unspecific protease. Using such protease allows to spot the 
most flexible regions of a protein regardless the protein sequence thus providing a distinct 
assessment of protein global/local flexibility from the experiments described above. 
Our preliminary findings are consistent with trypsin experiments revealing H LCs to be proteolysed 
faster than M LCs (Figure 2.7). Usually, H LCs showed a final amount of uncleaved protein lower 
than 20% while for M7 was more the 40%. However these experiments need to be performed for 
all the LCs in the pool and repeated in triplicate.  
 
Figure 2.7: LCs Limited proteolysis kinetics using PK.  
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2.2.4 Structural characterization 
 
2.2.4.1 LCs structure 
 
In order to structurally characterize H and M LCs, we carried out crystallization trials. Specifically, 
we achieved crystals of five H LCs (H3, H6, H7, H9, H10) and of two M LCs (M7, M8) (Table 2.3) and 
their 3D-structures were determined. 
 
Table 2.3: LCs crystallization conditions. * M7 was crystallized by micro-seeding using M8 crystals 
as seeds. 
 
LC ID Buffer pH Additive Precipitant Purchased from 
H3 6.5 0.1M Sodium cacodylate 27% w/v PEG 2000 MME 
Stura screen 
(molecular 
dimensions) 
H6 9.0 0.1M Bicine 10% w/v PEG 20K, 2% w/v 1,4-Dioxane 
Crystal screen I/II 
(Hampton) 
H7 7.5 0.1M HEPES 10% 2-propanol, 20% w/v PEG 4K JBS screen (Jena bioscience) 
H9 5.5 0.1M Sodium citrate 16%w/v PEG 4000, 10% v/v 2-Propanol 
Stura screen 
(molecular 
dimensions) 
H10  0.05M KBr 30% PEG 2000 
JCSG screen 
(molecular 
dimensions) 
M7 * 4.0 0.1M MMT (Malic acid, MES and Tris-based buffer) 25% w/v 1.5K 
PACT screen 
(molecular 
dimensions) 
M8 4.6 0.2M Sodium acetate, 2.0M NaCl  
Crystal screen I/II 
(Hampton) 
 
X-ray diffraction analyses revealed that LCs crystallized in different space groups with different 
crystal packing and ranged in resolution between 1.65 Å (H9) and 2.70 Å (H7) (Oberti et al., 2017 
Table S2). As expected, in all cases the LCs quaternary arrangement was dimeric (Figure 2.8 A). 
Indeed, several experimental approaches, such as mass spectrometry, confirmed LCs to be covalent 
dimers joined by a S-S located at the C-terminus (Kaplan et al., 2009),  however due to local 
flexibility, this S-S was visible only in the structure of H9.  
Vl and CL showed different structural properties. CL domains are always characterized by a well-
defined electron density. On the contrary, electron density was not always entirely detectable for 
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Vl. In particular, its quality in the CDR loops is markedly dependent on the LC crystal structure and 
on the crystal packing. In fact, the six CDRs (three for each monomer) were completely traceable in 
H6 and M8 structures; in the ones of H9 and H10 five out of six CDRs were modeled; three in H7; 
just two in H3 and M7. Generally CDRs tend to be solvent exposed in all the LC structures. These 
differences among the CDRs electron density are probably due to the different crystal packing and 
crystal growth conditions.  
In summary the electron density for CL domains is of similarly good quality in all the seven structures 
and suggest that CL domains are highly rigid. ,Conversely, VL domains present different level of 
flexibility and CDR conformations. However, the presence of well-defined CDRs, the ability to form 
crystals or the quality of crystals – in terms of diffraction - do not correlate with the fold stability 
flexibility in solution or aggregation propensity. Indeed, the low stable H6 presents six out of six 
traceable CDRs while the more stable H9 and H10 just five. This means that crystallographic studies 
on CDR do not allow to fully appreciate the high flexibility of these regions. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.8: (A) Cartoon represented the conserved overall quaternary structure of H9 as example 
of LC structure. (B) Zoom into the well-defined electron density of C215-C215 disulphide bond 
(sticks representation) and the surrounding C-terminal residues (lines representation). 
 
 
2.2.4.1 Structural comparison studies 
 
With a focus on possible differences between H LCs and M LCs structures, a detailed structural 
comparison was performed. 
A B 
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First, we compared the LCs FL structures. We observed that CL and VL domains are differently 
oriented with respect to each other due to the bending of the joining region. In particular, this angle 
is known as elbow angle and the values spanning from 107.99° (H7) to 157.36° (M8). Because of 
such a high structural variability the root mean square deviation (r.m.s.d) analyses on the FL LCs are 
not meaningful. Therefore, the comparison analyses were carried out separately on VL-VL dimers 
and CL-CL dimers. 
The superposition on CL-CL LCs domains suggested that they are conserved not only in the sequence 
but also from the structural point of view (Figure 2.9 A). Indeed, their comparisons showed r.m.s.d 
values generally around 1.0 Å over the entire dimer.  
The superposition of the VL domains s revealed that the VL monomers match closely, while the CDRs 
conformations are rarely superposable (Figure 2.9 B). In particular, we observe CDR3 to be the most 
differently oriented in the space.  
 
 
 
 
 
 
 
 
 
 
Figure 2.9: (A) Superposition analyses of the LCs structures, VL-VL in the upper part and CL-CL in the 
bottom. The fixed chain is reported in gray. (B) Superposition of VL monomers with the three CDR 
highlighted.  
 
The VL-VL domains interface was also evaluated by means of structural comparisons and Protein 
Interfaces, Surfaces and Assemblies (PISA) analyses (Krissinel, 2015). First, comparison analyses 
revealed a conserved sub-set of amino acids involved in the interface (Figure 2.10 A). Moreover, the 
same approach showed that in all our H structures and in M7, the interface is symmetric and takes 
place on the five-stranded β sheet. In particular strands 3, 4, 7, 8 build the intermolecular contacts. 
Only M8 VL-VL presented a different interface because one of the two VL domains is rotated. 
A B 
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Specifically, this rotation leads the M8 interface to be asymmetric (Figure 2.10 B). Indeed, on the 
rotated VL domain only strands 1 and 8 provide intermolecular contacts. Interestingly, asymmetric 
VL-VL interface was already described in literature but only on the crystal structures of isolated VL 
dimers (Blancas-Mejía et al., 2017b) (Figure 2.11).  
 
 
 
Figure 2.10: (A) Monomeric VL showing the strands involved in the interface (purple) with 
conserve amino-acids subset; (B) VL-VL H9 (blue) and M8 (lime) superposition, the interface of M8 
is significantly asymmetric with respect to the H9 one; (C) VL-VL M8 and VL-VL 5T93 (Blancas-
Mejía et al., 2017b) superposition, both the VL-VL dimers present asymmetric interfaces with one 
M8 VL 180° rotated respect to the 5T93 one. 
 
 
Figure 2.11: Different amyloidogenic LCs dimer interfaces. κI (gold), AL-12 (blue), AL-103 (red),  AL-
09 (black), and AL-T05 (orange) (PDB codes 2Q20, 3DVF, 3DVI, 2Q1E, and 5T93, respectively). 
Structures were superimposed using one monomer (surface, cyan) of the homodimer (adapted from 
Blancas-Mejía et al., 2017b). 
 
We further characterized the interface performing a PISA analysis. This approach allows to compute 
the VL-VL dimers energy formation and the interface areas. Our findings suggested that there is no 
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correlation between the free energy gain in VL-VL dimer formation or the interface surface area 
with protein stability or aggregation propensity. For example, M8, which is the most stable LC 
against temperature, showed the smallest dimer interface area with the lowest calculated free 
energy change for quaternary assembly, compared to all other considered LCs.  
Together these data revealed the overall quaternary assembly and VL-VL interface to be overall 
conserved between H and M LCs. Therefore, we concluded that structural traits are not correlated 
with aggregation propensity. 
 
Table 2.4: Table showing the calculated chain A and chain B i) solvation energy and ii) the dimer 
interfaces. 
  
LC ID Solvation energy, 
chain A (Kcal/mol) 
Solvation energy, 
chain B (Kcal/mol) 
Dimer interface, 
chain A (Å2) 
Dimer interface, 
chain B (Å2) 
H3 -9.2 -9.3 1504 1486 
H6 -7.3 -7.6 1500 1458 
H7 -9.0 -7.6 1316 1352 
H9 -7.7 -7.6 1506 1507 
H10 -12.1 -11.3 1670 1671 
M7 -8.9 -8.9 1300 1307 
M8 -6.8 -8.7 1137 1125 
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2.3 H LCs biophysics and structure: discussion  
 
To date, the molecular properties linking H LCs sequence to aggregation propensity have not been 
identified. Likely this is because aggregation propensity is complex phenomenon due to several 
concomitant properties and studies aiming to understand LC aggregation propensity should take in 
account many parameters. Indeed, our study evaluated several biophysical and structural 
properties of H LCs. However, the common denominator of this complexity is the high sequence 
variability among LCs.  
From the biophysical point of view, our findings suggested that H LCs typically possess lower fold 
stability than M LCs (Figure 2.12 A). These data are in agreement with previous findings reported in 
literature (Costanzo et al., 2014): low fold stability facilitates aggregation because of the low  energy 
required for proteins to unfold compared to proteins characterized by high fold stability. Other 
works also underlined the same tendency even though the experiments were performed only on 
isolated VL (e.g., Marin-Argany et al., 2015). However, the correlation we observed between fold 
stability and aggregation propensity is not 100%, thus this biophysical property may contribute in 
determining LC aggregation propensity but cannot be considered the only cause of it. 
Our findings also indicated that LCs do not present any hydrophobic patches on their surface. 
Moreover, we demonstrated the hydrophobic core to be exposed in a single-step unfolding process, 
underling that the two domains do not present independent unfolding pathways. Interestingly, the 
absence of surface hydrophobicity is not surprisingly. Indeed, in literature several reports indicated 
that in many cases the aggregation propensity may be due to electrostatic (not hydrophobic) 
interactions (Déret et al.,1997).  
Additionally, we highlighted that H LCs tend to be more flexible than M ones (Figure 2.12 B). This 
findings are in keeping with other studies where it is well reported that amyloidogenic LCs are less 
kinetically stable and therefore more susceptible to endoproteolysis rather than non-amyloidogenic 
ones (Morgan and Kelly, 2016). Interestingly, the low kinetic stability could be due to the non-
correct or non-complete LCs folding which leads to protease-sensitive conformations. In particular, 
this property has been demonstrated to increase the aggregation propensity (Morgan et al., 2017).  
From the structural point of view we concluded that there are no major structural determinants, 
which could anticipate amyloidogenicity. Indeed, we assessed that the tertiary and quaternary 
assemblies of the seven LCs here presented are highly comparable and conserved. Interestingly, this 
finding suggested that the biophysical differences observed mainly depend on sequence variability 
rather than on structural rearrangements.  
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However, it must be noted that the most thermal unstable and trypsin sensitive LCs of our pool (H3, 
H6, H7 and H9) have been successfully crystallized. This underlines that despite the low fold stability 
and high flexibility these proteins presented a properly folded native state. 
From these data, we concluded that the in vivo aggregation propensity cannot be associated to a 
specific biophysical parameter. On the contrary, we highlighted that at least two different 
properties, fold stability and protein flexibility, appear to be related with it. Therefore, our findings 
suggest that the LCs amyloidogenic behavior may be determined by the interplay of several 
biophysical properties of native LCs (Figure 2.12 C). 
 
 
 
Figure 2.12: (A) Average of H LC and M LC melting temperatures. (B) Average of the H and M 
uncleaved protein fraction at 180 min after limited proteolysis; *** p-value < 0.0005;                                                        
** p-value < 0.005. (C) Graphical representation of the biophysical properties contributing in the 
amyloidogenic properties. 
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2.4 Role of Copper in LCs toxicity and aggregation propensity 
 
2.4.1 Background 
 
2.4.1.1 The role of Cu2+ in amyloid-related diseases 
 
To date, several studied aimed to dissect the role of Cu2+ in amyloids-related diseases are reported 
in literature. Among them, it takes particular relevance the neuro-biochemistry research. Indeed, 
Cu2+ activity was extensively studied within Alzheimer disease (AD, amyloid β ), Parkinson disease 
(PD, α-synuclein), Huntington disease (HD, huntingtin), and congophilic amyloid angiopathy (CAA).   
Indeed, in physiological conditions, Cu2+ is present in brain and it is used by a widely number of 
enzymes as catalyzer. At the contrary, in disease,  abnormal levels of Cu2+ ions are detected in the 
brain. Indeed, a high Cu2+ concentration is toxic and associated with neurodegeneration (Capanni 
et al., 2004; Hashimoto et al., 1999; Paik et al., 1999; Uversky et al., 2001; Tiffany-castiglioni et al., 
2011). 
Specifically, the role of these ions has been established to influence protein aggregation: it can 
increase or decrease the aggregation propensity depending on the system where it is involved.  
For instance, Cu2+ is linked with a reduced amyloid fibril formation in AD and CAA. In AD Cu2+ has 
been reported to prevent the assembly of amyloid- β1-42 (αβ42) into amyloid fibrils both at sub-
stoichiometric or molar excess (Mold et al., 2013). Moreover, it has also been demonstrated that 
αβ42 native form is stabilized through Cu2+ and Hydrogen peroxide Induced Cross-linking of 
Unmodified Proteins (CHICUP) (Williams et al., 2016). In details, the crosslinked stabilized dimer 
shows an attenuated fibril formation and thus should be further explored as a new therapeutic 
target (Williams et al., 2016). It is also worth to mention that in AD, as well as in CAA,  recent studies 
(e.g., schrag  et al., 2011) demonstrated that lower Cu2+ leads to a more severe amyloid pathology 
and therefore that Cu2+ acts as a kind of protective agent. 
However, for other neurodegenerative diseases Cu2+ does not show a protective effect. For 
example, in HD huntingtin aggregation propensity is increased when Cu2+  levels are increased in 
the brain (Xiao et al., 2013). Moreover, in PD, α-Synuclein aggregation rate has been  demonstrated 
to be dependent on Cu2+ concentration (e.g., Ranjan et al., 2017). Indeed, Wang and coworkers 
reported that Cu2+ appears to be important for both aggregation and cellular localization of α-
Synuclein. Specifically, high Cu2+ levels are associated to an increase in aggregates formation (Wang 
et al., 2010) 
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Beyond the neuro-biochemistry, Cu2+ has been demonstrated to be related with other amyloid-
related pathologies. Among these it is particularly interesting the case of β-2-microglobulin (β2m), 
a protein causing an amyloidosis form called “dialysis-related amyloidosis”. β2m amyloid fibril are 
found in the musculoskeletal system of patients undergo long-term dialysis treatment (Srikanth et 
al., 2009) Several works have correlated Cu2+ to the β2m aggregation propensity. For instance, 
Srikanth and coworkers reported that Cu2+ binding causes the β2m oligomerization into native-like 
dimers and tetramers. Moreover, it has widely demonstrated that Cu2+ organizes β2m oligomers 
but it released upon amyloid formation (Antwi et al., 2008; Srikanth et al., 2009). 
To conclude, Cu2+ presents different effect depending on the amyloidogenic system where it is 
involved. Its role is almost clarified for the disease reported above. Anyhow, future studies will be 
pivotal to understand its role in other amyloid-related disease and the reason why its effect can be 
either pro or anti amyloidogenicity. 
 
 
2.4.1.2 The role of Cu2+ in AL amyloidosis 
 
It is well established that metal ions plays a role in protein aggregation diseases (Hashimoto et al., 
1999; Paik et al., 1999; Uversky et al., 2001). In particular, in 2017 our collaborators from the Mario 
Negri Research Institute demonstrated that copper ions (Cu2+) seem to be relevant for LCs toxicity. 
Specifically, they assessed that Cu2+ drives LCs-mediated ROS toxicity.  
Caenorhabditis elegans was used as in vivo system. Specifically, this system allows assessing LCs 
cardiotoxicity in the worm pharynx which is evolutionary related to the human heart (Mango, 2007). 
In particular, the pharynx pumping rate is evaluated i.e. the number of pharynx’s terminal bulb 
contractions.  
Using this approach, it was shown that H LCs exerts an increased toxic effect on worms when 
administrated together with Cu2+ rather than alone, as indicated by the marked decrease in the 
pumping rate in presence of H LCs pre-incubated with Cu2+. On the contrary, M LCs in presence of 
Cu2+ did not show altered pumping rate compared to control worms or the ones fed with H LCs 
alone (Figure 2.10).  
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Figure 2.13: Histogram showing the effects on the C. elegans pumping rate of (A) vehicle and ions 
administer alone (Cu2+, Fe2+ and Zn2+), (B) cardiotoxic H LC administered with ions, (C) non-
cardiotoxic Myeloma M LC administered with ions. Adapted from Diomede et al., 2017. 
 
Moreover, in order to prove a direct role for Cu2+ in H LCs toxicity in vivo, the proteins were co-
administered to worms with specific metal chelator agents. The results highlighted that the toxicity 
is abolished when Cu2+ is not available, as indicated by the increase in pumping rate values. 
These observations suggest that H LCs toxic mechanisms are linked with Cu2+ and their co-
administration results in high LCs toxicity in vivo. We aim to understand the biochemical basis of 
this effect using in our investigation H7 as toxic LC model and M7 as the non-toxic one according to 
Diomede et al., 2017. 
 
2.4.2 H LCs Cu2+ interaction 
 
In order to assess whether H LCs and Cu2+ establish a direct and specific complex we tested H7 by 
means of microscale thermophoresis (MST). This technique is aimed to study biomolecular 
interactions e.g., protein-protein, protein-ligand and protein-DNA. Specifically, it evaluates by 
fluorescence the molecules movement along a temperature microgradient, which results in 
different migration velocities when ligands are bound or non-bound.  
Our findings indicated that, among a large set of ions (Cu2+, Mg2+, Fe2+, Ca2+, Zn2+), Cu2+ is the only 
one interacting by H7 showing a Kd in the nanomolar range (~700 nM) (Figure 2.14 A). 
Moreover, with the aim to assess whether H and M LCs present different affinity for Cu2+, the 
binding between M7 and Cu2+ was also studied by MST. Surprisingly, the Kd measured for M7 was 
a hundred times lower than the one determined for H7, with a value of ~70 µM (Figure 2.14 B).  
A B C 
 50 
 
 
Figure 2.14: Thermophoresis analyses. (A) H7-Cu2+ binding curve (green) and Mg2+, Fe2+, Ca2+, Zn2+ ; 
(B) H7-Cu2+ binding curve (red) compared with M7-Cu2+ (green). 
 
Our data suggest that the increased H LCs toxicity in vivo may be the result of a direct and specific 
interaction between H7 and Cu2+. In particular, we assessed that this interaction occurs with 
higher affinity in a H LC rather than a M LC. 
Then, we wanted to shed light on the Cu2+ binding site to H LCs. In particular, we considered the 
role of His residues since in literature their involvement in the metal ion coordination is well 
established (Lee et al., 2018). Our findings showed that at pH 5.5, when His residues are in their 
protonated state, the Cu2+ binding affinity is markedly decreased. Indeed, the measured Kd (~ 70 
µM) resulted to be a hundred times lower compared to the one measured at pH 7.5 where His 
residues are in their non-protonated state (Kd ~ 700 nM) (Figure 2.15 A). Moreover, Kd value at pH 
5.5 is curiously reminiscent of the one measured for M LCs (Figure 2.15 B). 
 
 
A B 
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Figure 2.15: Thermophoresis analyses. (A) Comparison between H7-Cu2+ at pH 7.5 binding curve 
(red) with H7-Cu2+ at pH 5.5. (B) Comparison between H7-Cu2+ at pH 7.5 (red) with H7-Cu2+ at pH 
5.5 (green) and M7-Cu2+ at pH 7.5 (blue). 
 
These results have been further corroborated by in vivo experiments (Mario Negri Research 
Institute). The pharyngeal pumping rate in C. elegans is affected by the co-administration of Cu2+ 
and H7 at pH 7.5 while at pH 5.5 H7 seems to lose the most of its toxicity (Figure 2.16). These data 
strongly suggest that His residues may be involved in the binding of Cu2+ to H7. 
 
 
 
 
 
 
 
 
 
Figure 2.16: Histogram showing the pharyngeal pumping rate in C. elegans: toxicity tests performed 
at pH 5.5 show a markedly decreased protein toxicity compared to the same tests carried out at pH 
7.4.  
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Then, we evaluated the His residues positions in the LCs sequences and their location in the H7 
crystal structure. First, all the LCs belonging to our pool present two conserved His residues located 
in CL domain. H3, H9, H10, H15, H16, H18, M7 and M10 have a further one located in the VL and 
H15 and M8 present two more His residues in the Vl. Thus, we inspected H7 sequence and analyzed 
the His residues in H7 crystal structure. Figure 2.17 shows the position of H188 and H197 in the H7 
CL domains. In particular, H188 is structurally located in the loop between strands E and F and its 
side chain in the crystal structure was found to be completely solvent exposed. H197, it is located 
in the loop between strands F and G and appears to be partially solvent exposed. Thus both H188 
and H197 are properly positioned to interact with metal ions; further experiments will be carried 
out to identify the residues responsible for Cu2+ binding. 
 
Figure 2.17 H7 CL crystal structure showing the His residues positions. H188 is slightly more solvent 
exposed than H197.  
 
2.4.3 Fold stability in presence of Cu2+ 
 
The effect of Cu2+ on H7 and H6 fold stability was evaluated. In particular, this approach allows 
studying the thermal stability by following Trp fluorescence while temperature increases up to 80°C. 
Our findings show an overall destabilization of the protein in presence of Cu2+, as indicated by the 
Tm values (Figure 2.18 and Table 2.3). We performed these experiments at pH 5.5 and at pH 7.5 in 
presence or absence of Cu2+. These experiments reveal that both H7 and H6 are more stable at pH 
5.5 than at pH 7.5 and that Cu2+  destabilizes the two proteins under all tested conditions. 
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Figure 2.18: (A) Thermal unfolding ramps; (B) First derivative of the unfolding curve in A where the 
maximum indicates the Tm. Cold colors refer to protein in absence of Cu2+, warm color refer to 
protein in presence of Cu2+. It is worth to note that the warm colored curves are shifted toward 
lower temperatures underlining the Cu2+ destabilization effect. 
 
Table 2.3: Table showing the measured Tm (°C) for H6 and H7 at pH 7.5 and 5.5 in presence or 
absence of Cu2+. 
 
LC ID Tm (°C) pH 5.5 
-Cu2+ 
Tm (°C) pH 5.5 
+Cu2+ 
Tm (°C) pH 7.5 
-Cu2+ 
Tm (°C) pH 7.5 
+Cu2+ 
H6 52.6 45.0 50.3 47.0 
H7 50.0 46.0 47.0 46.0 
2.4.4 Protein flexibility in presence of Cu2+ 
 
With the intention of evaluating protein flexibility in presence of Cu2+ we analyzed H7 by the 
spectroscopic technique Red Edge Excitation Shift (REES). REES is an optical phenomenon where low 
energy excitation of a ﬂuorophore (often Trp for proteins) leads to a red shift in the maximum of 
the emission intensity (Catici et al., 2016). This phenomenon appears when a fluorophore shows a 
range of discrete solvation states and therefore it potentially reflects the equilibrium of 
conformational states (Chattopadhyay and Haldar, 2014). Therefore, a high molecular ﬂexibility 
degree corresponds to a big red shift and it is described by the ensemble of solvent environments 
around the Trp probe (Catici et al., 2016). 
Our findings suggested that the Cu2+ binding to H7 promotes an increase in flexibility. In particular, 
at pH 7.5 and in presence of Cu2+, H7 acquires a different conformational state as indicated by a 
shift of ~3 nm in CSM values (Figure 2.19 B compared with Figure 2.19 D), which could be referred 
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to an increased degree of flexibility. On the contrary at pH 5.5 the spectrum of H7 did not show 
significant alterations in CSM (shift < 1 nm) indicating that not the presence but the binding of Cu2+ 
affect the protein flexibility (Figure 2.19 A compared with Figure 2.19 C). These observations fit well 
with the data on pH dependent Cu2+binding and with the pH dependent toxicity of H7.  
 
Figure 2.19: REES analyses of H7 in absence of Cu2+ at pH 5.5 (A) or 7.5 (B) and in presence of Cu2+ 
at pH 5.5 (C) or 7.5 (D). 
 
2.5 LCs and Cu2+: discussion 
 
As already discussed, Diomede and coworkers highlighted a role for Cu2+ in LCs toxicity (Diomede et 
al., 2017). Our data start to shed light on the molecular bases of such effect. They reveal that Cu2+ 
binds H LCs and we provided a possible molecular mechanism for this interaction. Our findings 
suggested that this binding may be coordinated by His residues. Indeed, we assessed that in 
presence of unprotonated His residues the binding occurs and results in a gain in flexibility and 
toxicity in vivo. As proof of this assertion we demonstrated that when His residues are protonated 
the binding affinity utterly decrease and the toxicity is lowered.  
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Finally, we assessed that the presence of Cu2+ results in a decreased fold stability. Specifically, this 
effect occurs both when His residues are protonated or not.  Likely, this is the result of an unspecific 
effect probably due to the free Cu2+ in solution. Therefore, further experiments will be set up to 
address this issue. 
Interestingly, these results agree with our previous data showing the specific properties of H LCs 
compared to non-toxic ones. Indeed, we reported that toxic LCs tend to be less stable and more 
flexible with respect to the control. In this view the in vivo toxicity observed in presence of Cu2+ may 
be due to a gain in flexibility and lower fold stability.  
Unexpectedly, although M LCs present two His residues in the same location as H LCs, Cu2+ binding 
affinity is a hundred time lower. Likely, this may be referred to different local properties of His 
residues (i.e. flexibility) in H and M LCs. However, further experiments will be aimed to address this 
issue.  
The role of Cu2+ in LC toxicity here reported fits well several reports in literature where the role of 
metal ions is described as connected to the fibrillation process in aggregation diseases. Indeed, in 
2004 the human muscle acylphosphatase was used as protein model to study the effect of metal 
ions on the aggregation propensity. In particular, it was observed that Cu2+ produces a 2.5-fold 
increase in aggregation kinetics (Capanni et al., 2004). Another interesting evidence comes from Lee 
and coworkers regarding the role of Zn2+ to promote the formation of toxic oligomers in Alzheimer 
Disease. Additionally, other studies found metal ions, including Cu2+, responsible for the in vitro 
aggregation of α-Synuclein, a protein related to Parkinson disease (Hashimoto et al., 1999; Paik et 
al., 1999; Uversky et al., 2001). Moreover, Cu2+ is reported to be involved in the beta-2-
microglobulin amyloid fibers formation (Calabrese et al., 2008). Specifically, in this context Cu2+ 
promotes the formation of the aggregation-prone intermediates. 
While our data show that the interaction between an H LC and Cu2+ leads to I) an increased toxicity 
mediated by a lower fold stability, II) increased protein flexibility and III) ultimately in a marked 
protein toxicity; the precise molecular events underlying the increased toxicity are not fully 
described by our experiments. Two likely hypotheses may be drawn: that Cu2+ induces/stabilizes the 
formation of toxic oligomers or that the destabilization due to Cu2+ may facilitates H LCs proteolysis 
resulting in the formation of toxic peptides. Further experiments will be required to address these 
crucial issues. 
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3 FUTURE PERSPECTIVES  
 
Our data suggest that the co-action of several biophysical traits and external ligands play a role in 
defining the aggregation propensity and protein toxicity. 
Starting from data produced during this three-years PhD project, the biophysical properties of H and 
M LCs will be further investigated. In particular, this will be better assessed by experimental as well 
as computational techniques. 
We plan to point out the pivotal connection between molecular flexibility / thermodynamics and 
the pathogenic mechanism of AL. Technically, this could be achieved by means of several 
approaches. First, the production of a rationally designed mutant with lower thermal stability could 
provide information i) on  the role of this biophysical property in toxicity and pathogenesis and ii) 
on the relation between thermodynamics and protein flexibility. 
Then, the study of the first event(s) along the aggregation pathways involved in the pathogenic 
mechanisms may clarify the role of these two biophysical properties. In particular, it would be 
interesting to dissect whether the modulation of LCs thermal and kinetic stability might alter the 
release of  toxic and aggregation prone endoproteolytic fragments (Figure 2.20). 
 
 
Figure 2.20. Schematic representation of LCs fragments production. (Morgan and Kelly, 2016) 
 
 Technically, this could be achieved by the study of isolated and purified soluble LCs fragments. In 
particular, these fragments will be characterized by means of mass spectroscopy and then will be 
administered to human fibroblasts or to C.elegans to evaluate their toxic potential. Then, the study 
on their aggregation propensity could provide pivotal information on their role in the first events of  
AL pathogenesis. 
In parallel, the molecular effects of LC – Cu2+ interaction will be fully characterized and such 
understandings will also help in pinpointing out molecular events leading to protein toxicity. 
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To summarize, our long term goals are to draw the first event(s) along the aggregation pathway ad 
to understand how non-aggregated LC molecules exert their soluble toxicity: unfolding, aggregation 
of dimers, release of LC fragments upon proteolysis by extracellular proteases etc. may be the 
player(s) (or some of them) of this complex pathologic molecular misfolding leading to AL 
amyloidosis. 
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4 MATERIAL AND METHODS 
 
Patients’ samples. Urine and bone marrow plasma cells were isolated from patients at the 
Amyloid Research and Treatment Center, Foundation IRCCS Policlinico San Matteo (Pavia, Italy). 
Acquisition, storage and use of biological samples for research purposes were approved by the 
Institutional Review Board of Fondazione IRCCS Policlinico San Matteo Pavia; all methods were 
performed in accordance with the relevant guidelines and regulations. Written informed consent 
was received from participants prior to inclusion in the study. The presence of tissue amyloid 
deposits and amyloid organ involvement were defined according to the International Consensus 
Panel Criteria. LC cardiotoxicity was evaluated on the basis of clinical, echocardiography and 
biochemical parameters (Table S1). 
 
Cloning. All the cloning procedures were performed by Dr. Paola Rognoni (Amyloid Research and 
Treatment Center, Foundation IRCCS Policlinico San Matteo, Pavia, Italy) and by Dr. Martina Maritan 
(Department of Bioscience, University of Milan, Milan, Italy). 
 
Bence jones LC purification. LC were purified to homogeneity from 24h urine collection. Urines, 
immediately combined with 0.1% sodium azide (w/v), were centrifuged at 3000 x g for 30min. 
Ammonium sulfate was added to the supernatant (65% saturation) and, after overnight 
incubation, samples were centrifuged at 3000 x g for 30 min. the precipitates were solubilized in 
20 mmol/L sodium phosphate, pH 7.0, and dialyzed against the same buffer. All steps were 
performed at 4 °C. LC were purified by anion exchange chromatography on an AKTÄ Purifier® FPLC 
system (GE-Healthcare, Piscataway, NJ, USA), using a HiPrep16/10 Q FF column, equilibrated in 
20mM sodium phosphate, pH 7.0. Bound proteins were eluted with a 0 up to 1M sodium chloride 
linear gradient. H6, M2, M9 were purified using a cation exchanger column (HiPrep16/10 SP FF), 
equilibrated in 20 mM Tris-HCl, pH 8.0, and was eluted with a 0 up to 1M sodium chloride linear 
gradient. the homogeneity of the isolated species was assessed by 12% SDS-PAGE. The final 
protein concentration was determined using the Pierce BCA Protein Assay Kit (Termo Scientific, 
Rockford, IL, USA) and bovine serum albumin as standard. 
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Recombinant LCs production. Heterologous proteins were produced using BL 21 DE3 E.coli strain. 
1L culture was inoculated by one single E.coli colony and grown until an optical density ~ 0.6. LCs 
cloned on pASK-IBA33 plus were inducted with 0.43 µM Anhydrotetracycline while those ones 
cloned on pET21b, with 0.5 mM IPTG. The growth conditions were 4 hours at 37 °C after the 
induction. 
 
Recombinant LCs purification. LCs were find in the cytoplasm as inclusion bodies. The cells were 
centrifugated at 6500 rpm for 15 minutes and then resuspended in 70 mL of Buffer A (10 mM TRIS-
HCl pH 8.0, 1 mM ethylenediaminetetraacetic acid (EDTA), 1 mM phenylmethylsulfonylfluoride 
(PMSF)) The cell suspension was sonicated at 200 W for 6 min (Branson Sonifier 250) and then 
centrifuged at 18000 rpm for 15 minutes at 4°C. The inclusion bodies were resuspended in 15 mL 
denaturing buffer (Buffer A containing 6 M guanidinium chloride and 5 mM β-mercaptoethanol), 
and incubated under mild agitation at 4 °C for 4 hours and centrifuged at 30000 g for 15 min. LCs 
were refolded by a 20-fold dilution in 10 mM Tris-HCl pH 7.4, 1 mM EDTA, 1 mM PMSF with 5 mM 
reduced L-glutathione and 0.5 mM oxidized L-glutathione. The refolding buffer with the proteins 
were incubated over-night under agitation at 4°C. Then, the protein solution was centrifuged for 
18000 rpm for 15 min at 4°C, and the supernatant was dialyzed overnight against 10 mM TRIS-HCl 
pH 8.0 (10 mM Sodium acetate pH 6.0 for H6 and M8). The refolding procedure was followed by 
purification by means of ion exchange and size exclusion chromatography. In specific, H3, H7, H9, 
M7 (pI ~6.0) and M9 (pI 6.8) were purified by an anionic exchange chromatography by using a Q 
Sepharose® Fast Flow GE Healthcare 16/10. H6 and M8 (pI ~8.0) were purified by a cationic 
exchange using a SP Sepharose® Fast Flow GE Healthcare 16/10. The columns were equilibrated 
with buffer A (10 mM Tris-HCl pH 7.4 (anionic exchange) or 10 mM Sodium acetate pH 6.0 (cationic 
exchange). LCs were loaded and then eluted by a saline gradient from 0 to 1M NaCl. The proteins 
always eluted at 160 – 240 mM NaCl. The size exclusion chromatography was performed using a 
Superdex 75 10/300 GL. The column was equilibrated with 10 mM Tris-HCl pH 8.0 or 50 mM NaPi 
pH 7.4. LCs eluted at ~ 14 mL. The homogeneity of the protein preparation was assessed by 12% 
SDS-PAGE, following standard procedures. Recombinant LCs were biochemically characterized by 
linear MALDI-TOF mass spectrometry and circular dichroism analyses, in order to verify sequence, 
homogeneity and correct folding. Gel filtration analysis indicates that all LCs used in this work were 
dimeric in solution. 
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Circular dichroism spectroscopy. Circular dichroism experiments, in the Far- and Near –UV regions, 
were carried out on a J-810 spectropolarimeter (JASCO Corp., Tokyo, Japan) equipped with a Peltier 
system for temperature control. All experiments were carried out in 50mM sodium phosphate pH 
7.4. For the experiments in Far-UV region we used 200 µL of 0.2mg/mL LCs in a cuvette with a 
pathlength of 0.1 cm. Spectra were recorded from 260 to 190nm. Temperature ramps were 
monitored at 202nm for 1 hour. Temperature increased up to 80 from 20°C with a 60 °C/hour 
temperature slope. Spectra and temperature ramps were performed in triplicate for each LC except 
for M8 for which no BJ purified material is available. For the Near-UV region, protein concentration 
was 1mg/mL in cuvettes with a pathlength 1 cm. Spectra were recorded from 350 to 250nm, 
whereas temperature ramps were monitored at 288nm from 20 to 80 °C (slope 60 °C/hour). Tm was 
calculated as the first-derivative minimum of the temperature ramps.  
 
ANS fluorescence. ANS binding experiments were performed in 50 mM sodium phosphate pH 7.4, 
at 20 °C and at 0.1 mg/mL protein concentration. LCs were titrated with ANS to a final concentration 
of 100µM. After every addition, ANS fluorescence emission spectra were monitored at 390nm in 
the 420–550 nm range. Excitation and Emission slits were set at 5nm, with a scanning speed of 
50nm/min. When ANS concentration was 100µM, its signal was monitored at 490 nm for 1 hour 
while temperature increased up to 80 °C (temperature slope 60 °C/hour) in a 1 cm path length 
cuvette. 
 
Limited proteolysis. LCs at a concentration of 0.8mg/mL, were incubated with a bovine trypsin at 
37 °C in 50mM sodium phosphate, 1M urea at pH 7.4, for 3 hours. The molar ratio protease/protein 
was 1:100. The first sample was collected immediately after trypsin addition and then after 10ʹ, 20ʹ, 
30ʹ, 60ʹ, 90ʹ, 120ʹ, 150ʹ, 180ʹ. Each sample was diluted in denaturating and reducing sample buffer 
(NuPAGE, Invitrogen). Then, they were heated for 3 min at 95 °C and analyzed by SDS-PAGE. The 
uncleaved protein fraction was quantified by densitometry using ChemidocTM MP System (Bio-Rad). 
Several LCs presented a very fast kinetic of proteolysis. We used H3, H6, H7, H10 in order to verify 
whether the presence of 1M Urea was not partially or totally unfolding the proteins. First, the Far-
UV spectra are superposable to the ones without urea. Moreover, the temperature unfolding curves 
monitored by Far-UV indicate that the Urea concentration used is sub-denaturating. Indeed, in 
presence of Urea the unfolding process start at a temperature beyond 37 °C. These observations 
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further confirm that the fast kinetics of proteolysis were not artifacts related to excessive urea 
concentration. 
We analyzed H3, H6 and H9, which displayed very fast kinetics of proteolysis, also in the presence 
of 0.5M and 0M urea, confirming under both conditions a trend for very fast proteolysis. 
 
Crystallization and X-ray structure determination. LCs were crystallized using sitting drops or 
hanging drops techniques. Proteins at  8.5–10mg/mL were solubilized in 50mM sodium phosphate 
pH 7.4 at 20°C. Table 2.3 shows the conditions where crystals were obtained. X-ray diffraction data 
were collected at ESRF (European Synchrotron Radiation Facility of Grenoble–France) at the beam 
lines: ID29, ID30, ID23-2, BM14. XDS (Kabsch, 2010) and MOSFLM (Leslie et al., 1992)were used to 
process the diffraction data. The crystal symmetry was evaluated by POINTLESS (Evans, 2006) and 
the intensities were merged and scaled with SCALA (Project and Number 4, 1994). The crystal 
structures were determined by molecular replacement using PHASER, BALBES and MOLREP (Long 
et al., 2008; McCoy et al., 2007; Vagin and Teplyakov, 1997). Only for the molecular replacement of 
H7 a previously deposited on the PDB LC was used (pdb: 1JVK) as search model. Indeed, for the 
other molecular replacements LC structures determined in house were used. H9 initial model was 
generated by ARP-wARP (Perrakis et al., 2001). The initial models were subjected firstly to a rigid-
body refinement and then to a restrained and TLS refinement using Phenix Refine, Refmac and 
Buster (Adams et al., 2010; Murshudov et al., 1997; Smart et al., 2012). Manual model building 
including water picking and further structure analysis were carried out by means of Coot (Emsley 
and Cowtan, 2004). Dimer interface analyses was performed using PISA server (Krissinel and 
Henrick, 2007). Fab elbow angles were calculated with phenix.fab_elbow_angle49. Figures of 
crystallographic structures were done using PyMOL and CCP4mg (Winn et al., 2011). The atomic 
coordinates and the structure factors of the seven structures of LCs have been deposited in the 
Protein Data Bank: 5MTL (H3), 5MUD (H6), 5MUH (H7), 5M6A (H9), 5M76 (H10), 5MVG (M7), 5M6I 
(M8). 
 
Microscale thermophoresis. LCs lysine residues were labelled, using the covalent dye and protocol 
provided by the manufacturer (NanoTemper). Two-fold dilution series of Cu2+ were prepared, to 
have a final concentration range from 1.2 nM to 40.0 µM. The final LCs concentration was instead 
kept constant at 60 nM in all experiments. Assays were performed at 24 °C in 10 mM PBS, pH 8 
containing 0.05% Tween20, using standard-treated glass capillaries and the instrument Monolith 
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NT.115 (NanoTemper) with 20% LED intensity and medium MST power. The Kd of protein-ligand 
was then calculated with the following equation: 
 
𝐹 = 𝑈 +	(𝐵 − 𝑈) ∙ (	[𝑙𝑖𝑔𝑎𝑛𝑑] + [𝑝𝑟𝑜𝑡𝑒𝑖𝑛] + 𝐾9 − :([𝑙𝑖𝑔𝑎𝑛𝑑] + [𝑝𝑟𝑜𝑡𝑒𝑖𝑛] + 𝐾9); − 4 ∙ [𝑙𝑖𝑔𝑎𝑛𝑑] ∙ [𝑝𝑟𝑜𝑡𝑒𝑖𝑛]	)2[𝑝𝑟𝑜𝑡𝑒𝑖𝑛]  
 
where F indicates the measured fluorescence, while U and B represent the response values of the 
unbound and bound states, respectively. 
 
Red Edge excitation shift. REES measurement were recorded on a Varian Cary Eclipse fluorimeter 
connected to a circulating water bath (HAAKE K20) for temperature regulation. These experiments 
were performed at 25 °C in a 0.5 cm path length cuvette. Protein concentration was adjust for each 
sample in order to obtain an initial fluorescence of ~ 0.8 mAu and generally it was 1 mg/mL. A 3D 
emission spectra scan were recorded from 325 to 500nm. The starting excitation wavelength was 
292nm and then it was subsequently increased in 1 nm steps for a total of 13 scans. Excitation and 
emission slits were both set at 5nm and the scan speed at 500 nm/min. The corresponding buffer 
control was subtracted from the spectra for each experimental condition. 
Data were analyzed in function of the CSM. This parameter was calculated using the following 
equation: 
 𝐶𝑆𝑀 = 𝛴(𝑓𝑖	x	𝜆𝐸𝑚)𝛴(𝑓𝑖)  
 
where 𝑓𝑖 is the measured ﬂuorescence intensity and 𝜆𝐸𝑚 is the emission wavelength. 
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Concurrent structural and biophysical
traits link with immunoglobulin light
chains amyloid propensity
I performed the following experiments:
- Setting of the expression conditions and purification protocol for 
the recombinant LCs (H3, H6, H7, H9, M7, M8 and M9);
- Large scale production of H3, H6, H7, H9, M7, M8 and M9;
- Far-UV CD, Near-UV CD, ANS fluorescence (fold stability and 
surface hydrophobicity);
- Limited proteolysis and Red edge excitation shift (protein 
flexibility);
- Crystallization of H6, H9, H10, M7;
- Structure determination of H6, H9, H10, M7;
- Microscale thermophoresis: confirmation experiments on M7;
- Fluorescence assays (Fold stability in presence of copper).
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Concurrent structural and 
biophysical traits link with 
immunoglobulin light chains 
amyloid propensity
Luca Oberti1, Paola Rognoni2, Alberto Barbiroli3, Francesca Lavatelli2, Rosaria Russo4, 
Martina Maritan1, Giovanni Palladini  2, Martino Bolognesi  1,5, Giampaolo Merlini2 & 
Stefano Ricagno  1
Light chain amyloidosis (AL), the most common systemic amyloidosis, is caused by the overproduction 
and the aggregation of monoclonal immunoglobulin light chains (LC) in target organs. Due to 
genetic rearrangement and somatic hypermutation, virtually, each AL patient presents a different 
amyloidogenic LC. Because of such complexity, the fine molecular determinants of LC aggregation 
propensity and proteotoxicity are, to date, unclear; significantly, their decoding requires investigating 
large sets of cases. Aiming to achieve generalizable observations, we systematically characterised a 
pool of thirteen sequence-diverse full length LCs. Eight amyloidogenic LCs were selected as responsible 
for severe cardiac symptoms in patients; five non-amyloidogenic LCs were isolated from patients 
affected by multiple myeloma. Our comprehensive approach (consisting of spectroscopic techniques, 
limited proteolysis, and X-ray crystallography) shows that low fold stability and high protein dynamics 
correlate with amyloidogenic LCs, while hydrophobicity, structural rearrangements and nature of 
the LC dimeric association interface (as observed in seven crystal structures here presented) do not 
appear to play a significant role in defining amyloid propensity. Based on the structural and biophysical 
data, our results highlight shared properties driving LC amyloid propensity, and these data will be 
instrumental for the design of synthetic inhibitors of LC aggregation.
Systemic amyloidoses are protein misfolding diseases caused by deposition of proteins as fibrillar aggregates in 
target organs1. In these disorders, the amyloidogenic protein precursor is produced at sites distant from those 
of deposition, being then transported to the tissues through blood2. Light chain amyloidosis (AL) is the most 
frequent systemic form, with an incidence of approximately 10 cases per million-persons/year; it is caused by dep-
osition of excess monoclonal immunoglobulin light chains (LCs) produced by a bone marrow plasma cell clone3. 
Since the incidence of AL increases with age, the socio-economic impact of this devastating disease is expected to 
grow within the ageing population of industrialized countries.
AL is a heterogeneous disease, both in terms of causative proteins and of the pattern of organ involvement. 
The extreme variability among LCs, caused by genetic rearrangement and somatic hypermutation4, translates into 
the fact that virtually every monoclonal LC is unique in its amino acid sequence. The clinical phenotype of AL is 
also polymorphic, most patients showing multi-organ involvement at presentation2: involvement of the heart, in 
particular, is frequent (~75% of cases) and dictates the prognosis2,3,5. A growing body of experimental and clinical 
evidences from patients with cardiac involvement indicate that damage is not only caused by fibril deposits, but 
also by pre-fibrillar amyloidogenic LCs, which are themselves directly toxic for target cells6–9.
Understanding the specific properties of different LCs in their soluble native state, therefore, appears as a 
rational approach to explore the determinants of amyloid formation, organ tropism and dysfunction in vivo. 
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Because of insufficient insight, no treatments exist yet to block fibril formation and prevent tissues damage. In 
fact, the current therapeutic strategies are based essentially on halting the production of amyloidogenic LCs from 
the plasma cell clone by means of chemotherapy5.
Structural characterization has shown that LCs assemble into homodimers, each monomer consisting of two 
immunoglobulin domains10, where the N-terminal variable domain (VL) displays high sequence variability. In 
particular, the three hypervariable complementarity determining regions (CDR) that target specific antigens are 
located in the VL domain. The C-terminal constant domain (CL), on the contrary, displays highly conserved 
sequence within the λ and the κ isotypes. To date, most studies dealing with the biophysical and structural 
properties of amyloidogenic LCs have focused specifically on VL domains, as they are abundant in fibrils: typ-
ically, VL domains belonging to amyloidogenic LCs are thermodynamically and kinetically unstable, while the 
three-dimensional structures of amyloidogenic and non-amyloidogenic VL studied match closely11–15. However, 
many observations stress the relevance of studying full length LCs: (i) although VL are abundant in fibrils, the full 
length LCs and CL domains have also been found in deposits12,16–18; (ii) so far, FL LCs and not truncated forms, 
have been found soluble in blood and serum19; iii) recent reports underline the relevance of the CL domain in 
determining both the biophysical properties and the aggregation propensity of LCs20–23.
The biophysical characterizations hitherto reported have mostly focused on the pairwise comparisons of one 
amyloidogenic with one non-amyloidogenic LC11,16,20,21,24. At the light of the mentioned sequence variability4, 
the results of such studies may prove difficult to generalize. In an effort to extend our views, here we present 
a comprehensive biophysical and structural characterization of a pool of eight amyloidogenic LCs originating 
from different patients (thus endowed with different amino acid sequences). Among all patients who overexpress 
one LC variant, only a subset develops AL (specific germline genes typically of the λ isotype are overrepresented 
among amyloidogenic LCs25–27), therefore five LCs not displaying amyloid propensity in patients were included 
as controls in our test pool. We explored the correlation between the aggregation propensity observed in patients 
and the LC molecular properties that may elicit misfolding, and are held to be associated with proteotoxicity. Our 
results provide insight on the fundamental molecular properties of pathogenic LCs, and in parallel suggest con-
cepts for the design of therapeutic approaches to AL directly targeting circulating LC molecules.
Results
Set-up of the LC test pool. In order to explore a most general context, while coping with the issue of high 
LC sequence variability, we devised an experimental approach based on three criteria. (i) Our biophysical and 
structural characterization covered thirteen LCs from distinct patients. LCs were distributed in two groups: a 
set of eight amyloidogenic LCs responsible for severe cardiac involvement and symptoms in patients (hereafter, 
H LC), and a set of five non amyloidogenic LCs isolated from patients affected by multiple myeloma for which 
no amyloid aggregation or proteotoxicity was observed in patients (hereafter, M LC) (Table 1 and Table S1). 
(ii) All the selected LCs were of the λ isotype, which is overrepresented among amyloidogenic LCs (approxi-
mately 75%)2,28, all the H LCs (except H10 from germline 1–36) belong to germlines commonly found among AL 
patients29. However, the LCs were distributed across different families and germlines to avoid focusing on family/
germline-specific properties (Table 1 and Fig. 1). (iii) All proteins used in the experiments were full length LCs, 
since the blood concentration of these species in each patient directly correlates with the severity of organ dys-
function, particularly regarding the heart (Table S1)5,8. Our experiments focused on the properties of native LCs, 
since ultimately these represent the circulating reservoir of aggregation prone material; LCs were either expressed 
recombinantly30 or purified from patients’ urines (Table 2).
LC fold stability. Protein stability within the two LC groups was assessed using three different and comple-
mentary approaches. Unfolding temperatures for each LC were monitored by Far-UV circular dichroism (CD), 
LC code Germline Gender, age Diagnosis Organs involved Serum λ FLC (mg/l)
H3 1c (IGLV1-44) M, 65 AL H 252
H6 1b (IGLV1-51) F, 72 AL H, K, PNS 248
H7 1b (IGLV1-51) M, 45 AL H 477
H9 2c GLV2-8) M, 59 AL H, ST 699
H10 1a (IGLV1-36) M, 73 AL H, L 475
H15 6a (IGLV6-57) M, 53 AL H, PNS, ST 839
H16 2a2 (IGLV2-14) M, 72 AL H, K 383
H18 3 l (IGLV3-19) M, 69 AL H, ST, PNS 509
M2 2b2 (IGLV2-23) M, 65 MM — 1140
M7 3 l (IGLV3-19) F, 71 MM — 6130
M8 2b2 (IGLV2-23) M, 48 MM — 573
M9 2b2 (IGLV2-23) M, 61 MM — 8510
M10 2a2 (IGLV2-14) M, 55 MM — 12200
Table 1. Biochemical and clinical features of H and M LCs (for more extended information, with a complete set 
of clinical data, see Table S1). Abbreviations: M, male; F, female; MM, multiple myeloma; H, Heart; K, Kidney; 
ST, Soft Tissues; PNS, Peripheral Nervous System; BJ, Bence Jones protein (monoclonal urinary free light 
chains); FLC, Free Light Chains.
www.nature.com/scientificreports/
3ScieNtific RePORtS | 7: 16809  | DOI:10.1038/s41598-017-16953-7
by Near-UV CD, and by 8-anilino-1-naphthalenesulfonic acid (ANS) binding and fluorescence signal (Fig. 2). 
LC unfolding monitored through these spectroscopic methods provides information on the loss of secondary 
structure, of tertiary structure, and on the exposure of buried hydrophobic residues to the solvent, respectively. 
As previously reported the unfolding of full length LCs is not reversible (data not shown)22, thus all temperatures 
corresponding to the unfolding inflection points should be considered apparent melting temperatures (Tmapp). 
The Far and Near-UV spectra of all LCs under native conditions are shown in Fig. S1.
In general, H LCs (warm colours in Fig. 2) displayed lower Tmapp compared to M LC (cool colours in Fig. 2), 
as determined from the Far-UV and Near-UV CD temperature ramps shown in Fig. 2A and B, respectively. 
However, low Tmapp values do not correlate perfectly with LCs amyloidogenicity, since M7 and M10 LCs unfold at 
temperatures close to those of the most stable H LCs (Table 2). Interestingly, most LCs show a one-step unfolding 
process, but three H LCs (H3, H6, H7) and one M LC (M9) display a two-step process, observed both in Far- 
and Near-UV temperature ramps (Fig. 2A,B). At the protein concentration required for Near-UV experiments 
four LCs (H10, M2, M8, M10) precipitated before the unfolding process was complete, thus Tmapp could not be 
determined. Nevertheless, the Tmapp values obtained by monitoring the unfolding both by Near-UV and Far-UV 
CD, show a good agreement (Table 2), indicating that for these LCs the loss of secondary and tertiary structures 
are simultaneous processes. Student’s test calculated using Tmapp values determined by Far-UV indicate that the 
differences between H and M-LCs are significantly different (P < 0.005).
While the Near-UV CD signal is strongly dependent on Trp residues, and may therefore provide rather local 
information about the unfolding process, an increase in ANS fluorescence indicates the exposure of hydrophobic 
residues from the protein core. Inspection of Fig. 2C shows that unfolding monitored by ANS fluorescence is com-
patible with exposure of the hydrophobic core residues in a one-step process in all the analysed LCs. This observation 
rules out that stepwise unfolding of the two distinct domains occur in the LCs (H3, H6, H7, M9), which display 
Figure 1. Multialignment of all thirteen LCs used in this work: the residues conserved in all sequences are 
highlighted in yellow, residues involved in the VL – VL interface in all the crystal structures are highlighted in 
cyan, while the residues belonging to the three CDRs are shown in red.
LC Source Tmapp Far UV (°C) Tmapp Near UV (°C)1 ONSET ANS SIGNAL (°C) Hydrophobicity (%) Proteolysis2 Trypsin sites
H3 Rec (40.2) – 54.4 ± 0.8 (44.5)—53.1 54.8 23.1 +++ 14
H6 Rec (43.9) – 54.5 ± 0.8 (45.3)— 55.3 23.1 +++ 18
H7 Rec (42.8) – 54.7 ± 0.5 (48.7) – 56.2 54.8 23.6 ++ 16
H9 BJP 52.0 ± 0.8 54.0 55.8 21.3 +++ 14
H10 BJP 54.9 ± 0.5 54.3 58.3 23.7 ++ 14
H15 BJP 55.6 ± 0.6 — 54.7 21.8  + + 14
H16 BJP 51.3 ± 0.7 51.9 54.5 22.3 +++ 13
H18 BJP 52.4 ± 0.5 51.1 51.5 22.9 ++ 13
M2 BJP 61.5 ± 0.8 — 63.9 23.0 + 15
M7 BJP 54.7 ± 0.5 55.3 58.8 22.4 + 15
M8 BJP 72.6 — 73.5 22.7 + 15
M9 Rec/BJP (63.2) – 68.2 ± 1.4 (58.8) – 67.7 62.8 24.2 + 15
M10 BJP 58.0 ± 0.6 — 56.1 21.5 + 15
Table 2. Biophysical properties assessed for H and M LCs. Rec, recombinantly expressed LC; BJP, Bence Jones 
proteins purified from urines. (1): some Tmapp values could not be measured due to protein aggregation during 
the temperature ramp. (2): +++:  < 20%, ++: 20–60%, +:  > 60% fraction of uncleaved protein after 180 min.
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two-step unfolding when monitored by CD signal; thus the temperatures corresponding to the first inflection points 
are written in parenthesis in Table 2. The onset of the ANS signal, but not the inflection point of the curves, correlates 
well with the Tmapp values calculated from the CD signals; such apparent discrepancy suggests that the hydrophobic 
core is exposed only at an advanced state of unfolding, which leads to an (apparent) systematic Tmapp overestimation 
in ANS temperature unfolding. Taken together these data suggest that the loss of tertiary and of secondary structures 
are simultaneous processes, indicating that LC dimers unfold through a cooperative process. Importantly, the ANS 
spectra recorded under native conditions yield undistinguishable low signals (data not shown), suggesting that under 
such conditions none of the LCs studied in this work expose relevant hydrophobic patches to the surface.
LC dynamics. In order to obtain an indirect assessment of protein dynamics, limited proteolysis of the differ-
ent LCs using trypsin was performed. Typically, fast proteolysis kinetics correlate with marked protein dynamics; 
conversely, protein rigidity correlates with slow proteolysis kinetics. In our hands, many but not all of the LCs 
belonging to the explored set displayed an unexpected resistance to proteolysis by trypsin and chymotrypsin 
(data not shown); controlled shaking (i.e. simulating shear forces) was tested to increase the kinetics of prote-
olysis without any effect (data not shown). Thus, in order to perform proteolysis in an adequate time frame, a 
sub-denaturant concentration of urea (1 M) was added to the protein solutions: under such conditions all LCs 
displayed CD spectra indistinguishable from those recorded in the absence of 1 M urea (data not shown).
Figure 3 shows the SDS-PAGE monitoring the controlled proteolysis experiments and the plotted fraction 
of uncleaved protein at different time points. Analysis of the data shows that the kinetics of proteolysis correlate 
well with amyloid propensity (Fig. 3B): H3, H6, H7, H9, and H16 are almost or totally proteolysed after 60 min-
utes, and more than 50% of H10, H15 and H18 LCs is cleaved after three hours. This is in stark contrast with the 
behaviour observed for the five M LCs, which are consistently more resistant to trypsin, in all cases more than 
60% of the M LCs remaining uncleaved at the end of the experiment (total of 3 hours). The number of potential 
trypsin cleavage sites for each LC is reported in Table 2; such numbers vary and do not correlate with the kinetics 
of proteolysis, suggesting that the observed kinetics underlie genuine differences in protein dynamics or confor-
mational flexibility. Student’s test calculated using the percentage of uncleaved LC at the end of the experiment 
indicates that the kinetics of proteolysis between H and M-LCs are significantly different (P < 0.0005).
The pattern of proteolysis varied among different LCs. SDS-PAGE gel analysis showed that for most LCs no 
bands corresponding to specific LC fragments were present, indicating that the LCs had been directly proteolysed 
to small peptides; although in a few cases discrete bands were detected, they proved unstable over the entire pro-
teolysis experiment (Fig. 3A). Overall, these observations suggest that the proteolytic path is distinct in different 
LCs, and that no stable LC domains (e.g. VL, CL domains or other fragments) can be isolated during proteolysis 
under the conditions tested.
Figure 2. Thermal stability of H and M LCs. Far-UV (A) and Near-UV (B) CD temperature ramps of the two 
sets of LCs used in this study. (C) Temperature ramps followed using ANS fluorescence. The H and M LCs are 
shown with warm and cool colours, respectively.
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Structural analyses of H and M LCs. In order to gain high-resolution structural insight, all the thirteen 
LCs were screened for crystal growth. Five H LCs (H3, H6, H7, H9 and H10) and two M LCs (M7 and M8) were 
successfully crystallized and their 3D-structures solved. Each of the seven LCs crystallized in a different space 
group, with distinct crystal packing; the crystallographic resolutions achieved ranged from 2.70 Å (H7) to 1.65 Å 
Figure 3. (A) SDS-PAGE monitoring the limited proteolysis of H and M LCs by trypsin. The first sample was 
taken one minute after trypsin addition (1) and then at 10, 20, 30, 60, 90, 120, 150 and 180 min of reaction 
time. In LC a standard amount of the corresponding LC loaded onto the gel without adding trypsin (Tr). 
MM indicates molecular markers their mass is expressed in kDa. All SDS-PAGE were run under reducing 
conditions. Raw images of the all SDS-PAGE are shown in Figure S4 (B) Kinetics of LC proteolysis. The intensity 
of the band corresponding to the uncleaved LC has been quantified at different time points and plotted. As 
starting point the amount of protein present in the LC sample was chosen. Each curve results from three 
independent proteolysis experiments. The curves are colour coded as in Figs 2 and 3.
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(H9) (Table S2). The crystal structures were all refined to satisfactory refinement parameters (Table S2); in all 
cases the LCs were dimeric (Fig. 4A), with an overall quaternary arrangement closely matching that of the pre-
viously reported LC dimers10. Mass spectrometry and non-reducing SDS-PAGE indicated that 100% of the LC 
dimers were covalently linked by a disulphide bond located at the chain C-terminus (data not shown). However, 
due to underlying local flexibility, only for H9 a well-defined electron density for such C-terminal intermolecular 
disulphide bond is visible (Fig. S2).
VL and CL domains display very different structural properties in the seven crystal structures. CL domains 
(res 115–214) are typically characterized by high quality electron density, are all very well superposable, and 
the dimeric CL–CL arrangement is clearly conserved in all the analysed structures (root mean square deviations 
-r.m.s.d.- generally fall below 1.0 Å over the entire CL–CL dimer - Table S3A and Fig. 4B-bottom). The linker 
regions connecting VL and CL domains (residues 110–115) allow evident variability in the mutual orientation 
of VL and CL domains, which is described by the elbow angles (Table S2) spanning from 107.99° (H7) to 157.36° 
(M8). (Interestingly, the greatest elbow angles were found in the M LCs structures, as for previously reported 
works10. For this reason, the r.m.s.d. values calculated for the full length LCs are not meaningful and are not 
reported.
Contrary to what has been observed for the CL domains, the electron density quality for the VL domains 
(residues 1–109) greatly differs among the seven crystal structures. With the only exception of one of the two VL 
domains of the M7 LC dimer, the two β-sheets building the VL domains are in general easily traceable; however 
the quality of the electron density for the CDR loops is markedly dependent on the LC crystal structure consid-
ered. In H6 and M8 dimers all six CDRs (three for each LC monomer) are traceable in the electron density; in H9 
and H10 five out of six are traceable, in H7 three, and in H3 and M7 only two CRDs are traceable. Such different 
behaviours, which are related to the intrinsic CDR conformational adaptability, do not correlate with LC aggrega-
tion propensity or with the flexibility assessed by limited proteolysis. Thus, the observed variety of CDR confor-
mations are likely due to different CDR amino acid sequences, but may also reflect different chemical conditions 
for crystal growth and different crystal packing.
The above concept is further stressed by the fact the VL domain tertiary structures match closely (Table S3B 
and Fig. 4C), while conformations of their CDRs are rarely superposable. The inspection of the VL dimer provides 
a relevant example: the fine details of the VL–VL association interface are LC-specific, depending on: (i) sequence 
variability, which likely causes the mutual reorientation of VL domains by some degrees, as observed in the differ-
ent structures (Fig. 4B-top); and, (ii) CDR conformational variability (and traceability in the electron density). In 
some cases (H6, H9, H10) CDR3 (residues 89–97) participates in the interface; both CDR3s in the H7 dimer lack 
electron density, while in M7 and M8 CDR3 residues are located far from the VL–VL interface.
Despite these fine differences, all the structures here presented, except for M8, display an overall conserved 
VL–VL quaternary assembly and association interface (Table S3C and Fig. 4B and E). In the structures of all H LCs 
and in M7, the association interface is roughly symmetric, and is located on the five-stranded beta sheet (strands 
1, 3, 4, 7, 8), where the 3, 4, 7, 8 strands establish the intermolecular contacts. Figure 4D shows the region involved 
in the VL–VL interface together with the most relevant and conserved residues. Only the VL–VL interface in M8 is 
markedly different, one VL domain being rotated and resulting in an asymmetric VL–VL interface (Fig. 4E). As for 
the other structures, in one VL domain of M8 strands 3, 4, 7 and 8 participate to the dimeric interface, while only 
strands 1 and 8 of the facing/rotated VL domain provide association contacts.
The calculated free energy gain associated with dimer formation, and the resulting dimer interface areas 
(Table S4), do not correlate with amyloidogenicity. In particular, M8 LC, which is the most stable LC against 
temperature (Table 2), displays the smallest dimer interface area with the lowest calculated free energy change for 
quaternary assembly, compared to all other considered LCs (Table S4).
Discussion
The five M LCs presented in this study are found in patients at extremely high concentrations, much higher than 
the average concentration of the H LCs (Table 1 and S1), and yet, through the years, the M proteins remain soluble 
and do not aggregate. Our study aimed to explore the biophysical and structural properties that correlate with 
LC amyloid aggregation; to reach most general conclusions, we analysed a set of thirteen patient-derived LCs, 
focusing on some of the commonly proposed structural and biophysical determinants of protein aggregation and 
toxicity31, such as fold stability, protein overall hydrophobicity, protein dynamics and flexibility, and loss or heter-
ogeneity of 3D-structures. The first general conclusion we can draw from the data here presented is that none of 
such biophysical properties, taken alone, allows clustering of the H versus the M LCs; on the contrary, amyloido-
genicity seems to stem from the co-existence of more than one of the biophysical factors explored.
According to our assessments of fold stability through CD and ANS fluorescence, the examined H LCs dis-
play Tmapp values lower than the M LCs; on average the Tmapp for H LCs is 53.6 °C vs. an average Tmapp value of 
62.8 °C for the M LCs. Such a trend is mirrored by the average onset temperature for the ANS signal, which is 
55.0 °C for H LCs vs. 63.0 °C for the M LCs. Such an overall observation would be in keeping with the idea that 
amyloidogenicity correlates with lower fold stability, as previously suggested32; however, M7 and M10 are nota-
ble exceptions showing Tmapp values comparable with some of the H LCs. However, M7 was found present at 
high concentration in vivo, and yet no aggregation or toxicity was observed at presentation and during the later 
follow-up times (Table 1 and Table S1). This marked variability stresses the importance of using large set of pro-
teins and it likely explains the contained differences in Tmapp recently observed by others between amyloidogenic 
and M LCs23: Andrich et al. reports an interesting biophysical characterisation of nine full length LCs but only 
four are of the λ isotypes and thus could be compared23.
Intriguingly, the low ANS fluorescence observed under native conditions suggests that bulk surface hydropho-
bicity does not play a main role in determining the H LC toxicity in their native state. Indeed, LC overall hydro-
phobicity (computed from the amino acid sequences - Table 2) indicates a comparable amount of hydrophobic 
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residues in all thirteen LCs. The Far-UV CD spectra that on average display a slightly more intense signal for M 
LCs (Figure S1) suggest that typically the latter contain very regular β structure, while H LCs spectra vary more 
markedly; however, the inference value of these observations is essentially of qualitative nature.
Contrary to the limited information offered by the spectroscopic analyses, controlled proteolysis provided a 
robust indication that M LCs are more rigid, or less dynamic, than H LCs. These are however divided into two 
subsets: H3, H6 H7, H9 and H16 are very efficiently proteolysed, while H10, H15 and H18 show slower cleavage 
kinetics. Inspection of the SDS-PAGE gels shows that the proteolysis pattern is different in different H LCs, sug-
gesting that the sequence of proteolytic events, and not only their kinetics, may be characteristic of each H LC. It 
is also remarkable that fold stability and kinetics of proteolysis do not necessarily correlate: M7 displays the lowest 
Figure 4. (A) Cartoon model of the crystal structure of the H9 homodimer, as representative of the tertiary 
and quaternary organization of all the LC structures determined in this work. The two LC monomers are 
coloured in grey and blue. The VL interface region on the blue monomer is coloured in orange. The spheres 
indicate the position of N/C termini. (B) Superposition of the dimeric VL (top panel) and CL (bottom panel) 
domains. One VL/CL domain (coloured in grey) was fixed for all the seven structures and the second is coloured 
according to the different LCs (H3 yellow; H6 green; H7 dark blue; H9 blue; H10 magenta; M7 red; M8 lime 
green). VL domain from M8 is shown only in panel E. (C) Superposition of a single VL domain (grey) from each 
of the seven LC structures. The complementarity-determining regions (CDRs) belonging to different LCs are 
coloured following the B panel colour code. (D) Cartoon model of a single VL domain from the structure of H9 
showing in orange the regions involved in the VL – VL interaction. The residues represented as sticks indicate 
the positions involved in the VL – VL interface that are conserved among of all LCs structures. (E) Cartoon 
representation of H9 (grey-blue) and of M8 (grey-lime green) where the grey VL are superposed and oriented 
as in B (top panel). The different orientation of the second VL domain is apparent in the H9 dimer, chosen as an 
example, compared to the M8 dimer. Labels indicate the β-strand identification number.
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Tmapp among the M LCs, but also very slow proteolysis kinetics; H3, H6 and H9 show relatively high Tmapp, within 
the H group, but are almost instantly proteolysed by trypsin. Recently, Morgan et al. reported faster kinetics of 
proteolysis for three amyloidogenic LCs due to kinetic instability of the native state22. In the present study we 
cannot distinguish whether the different kinetics of proteolysis are due to thermodynamic or kinetic instability, 
which are anyway linked to increased protein dynamics.
Among the experiments here reported, limited proteolysis provided the best correlation between LC behav-
iour and amyloidogenicity, showing a pronounced proteolytic trend in the H LC group; such consideration may 
be relevant under different aspects. Increased protein dynamics is considered a risk factor for aggregation propen-
sity33. Furthermore, previous studies suggest that the LC fragments released by proteolytic cleavage of full length 
LCs are more amyloidogenic than the LCs themselves, and may be important species favouring the process of LC 
aggregation21,22,34. Indeed, the existence of LC fragments in amyloid deposits in vivo has been uncontrovertibly 
demonstrated4,34. Although the site (i.e. whether it occurs in the circulation, in the extracellular space or inside 
cells) and timing (before or after amyloid formation) of LC proteolysis is still a matter of debate, the strong cor-
relation between amyloidogenicity and the ability to be easily proteolysed is stimulating, and suggests that H LCs 
may release pathogenic peptides much more efficiently than M LCs.
Although crystals could not be grown for the whole set of LCs, the relevant number of crystal structures 
solved, allows us to extend the discussion to the relationships between the LC biophysical and structural prop-
erties. Firstly, and somewhat unexpectedly, the most temperature- and trypsin-sensitive LCs (H3, H6, H7, H9) 
could be successfully crystallized. Such results indicate that, although characterized by low stability and high 
dynamics within the group tested, these LCs display a properly folded native structure devoid of large disordered 
regions that would hamper crystal growth. Secondly, the high level of conservation of the tertiary and quaternary 
assemblies in the seven LC structures here reported strongly suggests that the differences observed in the biophys-
ical traits mainly depend on sequence variability, and not on major structural rearrangements. Such a considera-
tion would imply that the intrinsic sequence variability, mainly located in the VL domains, does not translate into 
extended conformational changes but is responsible for the LC behaviour at the molecular level (reflected by the 
biophysical traits and amyloidogenicity).
Intriguingly, plotting percentage of uncleaved LC at the end of the proteolysis experiments against Tmapp 
(determined by Far-UV) shows that H and M LCs could be clearly clustered (Figure S3). These observations 
suggest basic criteria for the design of ligands that may decrease LC amyloidogenicity. Molecules acting on the 
LC dimers, stabilizing the quaternary structure upon binding, as is the case of Tafamidis for the transthyretin 
tetramer (i.e. stabilization of the quaternary structure upon binding)35, would result in an increased LC fold sta-
bility, and in a reduction of overall protein flexibility, the two biophysical traits that were shown here to correlate 
more strongly with LC amyloid propensity. Specifically, within LC dimers, targeting the dimer region encompass-
ing the VL domains appears as the proper strategy to combat LC amyloidogenicity at its biophysical roots: indeed, 
small-molecule ligands stabilizing VL dimers have recently been shown to inhibit amyloid formation36.
In conclusion, analysis and comparison of the different biophysical properties of H vs. M LCs suggests that no 
single molecular determinant by itself can account for the observed toxicity and aggregation trends, thus stress-
ing the value of biochemical and biophysical studies based on a large pool of proteins rather than on pairwise 
comparisons. However, fold stability and protein dynamics (as assessed by proteolysis), but not surface hydro-
phobicity in the native state, or overall 3D-structure rearrangements of the native state, appear to play main roles 
in determining LC amyloidogenic behaviour. Our study therefore suggests that in vivo amyloidogenicity would 
be the result of concurrent biophysical traits that, as in our pool of proteins, may not necessarily all be present in 
each toxic LC at the same level.
Materials and Methods
Patients’ samples. Urine and bone marrow plasma cells were obtained from patients during routine diag-
nostic procedures at the Amyloid Research and Treatment Center, Foundation IRCCS Policlinico San Matteo 
(Pavia, Italy). Acquisition, storage and use of biological samples for research purposes were approved by the 
Institutional Review Board of Fondazione IRCCS Policlinico San Matteo Pavia; all methods were performed in 
accordance with the relevant guidelines and regulations. Written informed consent was received from partici-
pants prior to inclusion in the study. The presence of tissue amyloid deposits and amyloid organ involvement were 
defined according to the International Consensus Panel Criteria37,38. LC cardiotoxicity was evaluated on the basis 
of clinical, echocardiography and biochemical parameters39 (Table S1).
In parallel to amyloidogenic cardiotoxic LC (H), non-amyloidogenic LC from multiple myeloma patients (M) 
were used. All the monoclonal LCs included in the study, belong to the λ isotype.
Cloning of complete monoclonal free LC nucleotide sequences. Total RNA was extracted from 
107 bone marrow mononuclear cells using TRIzol reagent (Life Technologies, Paisley, United Kingdom). 
Monoclonal variable (VL) region nucleotide sequences were cloned by an inverse-PCR strategy that preserves 
the original sequence at 5′ and 3′ ends40. The PCR fragment was ligated into the pCR®2.1Vector (TA Cloning 
Kit; Life Technologies) and cloned into the TOP10 E. coli cells. After recombinant plasmid purification, insert 
was sequenced. In order to obtain the original full-length monoclonal LC (variable and constant regions, approx-
imately 650 bp, from codons +1 to +215), standard RT-PCR was employed using the same marrow RNA, a 
forward patient-specific primer (dictated by codons +1 to +7 of the monoclonal V sequence) and a universal 
reverse Cλ carboxyterminal cloning primer, corresponding to the last amino acids of the constant region (codons 
+208 to +215, 5′-TGAACATTCTGTAGGGGCCACTGT-3′). To determine the presumed germline genes of VL 
regions, sequence alignment was made with the current releases of EMBL-GenBank, V-BASE (V BASE Sequence 
Directory, MRC Centre for Protein Engineering, Cambridge, UK) and IMGT sequence directories. The gene 
sequences of the LCs here discussed have been deposited in the GenBank database: KC433670 (H3), KY471433 
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(H6), KC433671 (H7), KY471435 (H9), KY471432 (H10), KY471436 (H15), KY471437 (H16), KY471434 (H18), 
KY471441 (M2), KY471438 (M7), KY471439 (M9), KY471440 (M10).
LC purification from urines. LC were purified to homogeneity from 24 h urine collection. Urines, imme-
diately combined with 0.1% sodium azide (w/v), were centrifuged at 3000 x g for 30 min. Ammonium sulfate was 
added to the supernatant (65% saturation) and, after overnight incubation, samples were centrifuged at 3000 x g 
for 30 min. The precipitates were solubilized in 20 mmol/L sodium phosphate, pH 7.0, and dialyzed against the 
same buffer. All steps were performed at 4 °C. LC were purified by anion exchange chromatography on an AKTÄ 
Purifier® FPLC system (GE-Healthcare, Piscataway, NJ, USA), using a HiPrep16/10 Q FF column, equilibrated 
in 20 mM sodium phosphate, pH 7.0. Bound proteins were eluted with a 0 up to 1 M sodium chloride linear gra-
dient. H6, M2, M9 were purified using a cation exchanger column (HiPrep16/10 SP FF), equilibrated in 20 mM 
Tris-HCl, pH 8.0, and was eluted with a 0 up to 1 M sodium chloride linear gradient. The homogeneity of the 
isolated species was assessed by 12% SDS-PAGE. The final protein concentration was determined using the Pierce 
BCA Protein Assay Kit (Thermo Scientific, Rockford, IL, USA) and bovine serum albumin as standard.
Production of recombinant patient-derived LC. Recombinant LCs of selected patients were produced 
according to30. Briefly, heterologous proteins, produced in the cytoplasm as inclusion bodies, were retrieved and 
subjected to a renaturation procedure, followed by purification by means of ion exchange and size exclusion chro-
matography. Recombinant LCs were biochemically characterized by linear MALDI-TOF mass spectrometry and 
circular dichroism analyses, in order to verify sequence, homogeneity and correct folding. Gel filtration analysis 
indicates that all LCs used in this work were dimeric in solution (data not shown).
Circular dichroism spectroscopy. Circular dichroism experiments, in the Far- and Near –UV regions, 
were carried out on a J-810 spectropolarimeter (JASCO Corp., Tokyo, Japan) equipped with a Peltier system 
for temperature control. All experiments were carried out in 50 mM sodium phosphate pH 7.4. For the Far-UV 
region, protein concentration was 0.2 mg/mL in a cuvette with a pathlength of 0.1 cm. Spectra were recorded from 
260 to 190 nm, whereas temperature ramps from 20 to 80 °C (monitored wavelength 202 nm, temperature slope 
60 °C/hour). Spectra and temperature ramps were performed in triplicate for each LC except for M8 for which no 
BJ purified material is available. For the Near-UV region, protein concentration was 1 mg/mL in cuvettes with a 
pathlength 1 cm. Spectra were recorded from 350 to 250 nm, whereas temperature ramps from 20 to 80 °C (mon-
itored wavelength 288 nm, temperature slope 60 °C/hour). Tmapp was calculated as the first-derivative minimum 
of the temperature ramps. Spectra recorded on cooled samples after temperature ramps confirmed that LC dimers 
unfold irreversibly as previously reported22.
ANS fluorescence. 8-Anilino-1-naphthalenesulfonic acid (ANS) binding experiments were carried out at 
20 °C and at 0.1 mg/mL protein concentration in 50 mM sodium phosphate pH 7.4. Each experiment was per-
formed adding ANS to a final concentration of 100 µM. After every addition, ANS fluorescence emission spectra 
were recorded in the 420–550 nm range with excitation at 390 nm, excitation and emission slits were set at 5 nm, 
with a scanning speed of 50 nm/min. When ANS concentration was 100 µM, its signal was monitored at  490 nm 
along a temperature ramp starting from 20 to 80 °C (temperature slope 60 °C/hour) in a 1 cm path length cuvette.
Limited proteolysis. LCs at a concentration of 0.8 mg/mL, were incubated at 37 °C in 50 mM sodium phos-
phate, 1 M urea at pH 7.4, using a bovine trypsin/LC molar ratio of 1:100. The first sample was collected imme-
diately after trypsin addition and then after 10′, 20′, 30′, 60′, 90′, 120′, 150′, 180′. Subsequently, they were diluted 
in denaturating and reducing sample buffer (NuPAGE, Invitrogen), heated at 95 °C for 3 min and analysed by 
SDS-PAGE. Protein bands corresponding to uncleaved LC monomers were quantified by densitometric analysis 
using ChemidocTM MP System (Bio-Rad). In order to rule out that the very fast proteolysis of H3, H6, H7, H10 
was due to partial or total unfolding several controls were performed in presence of 1 M urea: first the Far-UV 
spectra are superposable to the ones without urea; secondly the temperature unfolding curves monitored by 
Far-UV indicate that the unfolding process is starting at a temperature beyond 37 °C. For three LCs (H3, H6 and 
H9), which displayed very fast kinetics of proteolysis, parallel experiments were performed also in the presence 
of 0.5 M and 0 M urea, confirming under both conditions a trend for very fast proteolysis for these H LCs (see 
Figure S1). The latter observations further confirm that the fast kinetics of proteolysis were not artifacts related 
to excessive urea concentration.
Crystallization and X-ray structure determination. LCs were crystallized using sitting drops or hang-
ing drops techniques. Each protein was solubilized in 50 mM sodium phosphate pH 7.4 at a concentration of 
8.5–10 mg/mL at 20 °C. Crystals were obtained in: H3: 0.1 M Sodium cacodylate pH 6.5, 27% w/v PEG 2000 MME 
(Stura screen, Molecular dimensions); H6: 0.1 M Bicine pH 9.0, 2% w/v 1,4-Dioxane, 10% w/v PEG 20 K (Crystal 
Screen I/II, Hampton); H7: 0.1 M HEPES pH7.5, 10% 2-propanol, 20% w/v PEG 4 K (JBS screen, Jena Bioscience); 
H9: 0.1 M Sodium citrate pH 5.5, 16% w/v PEG 4000, 10% v/v 2-propanol (Stura screen, Molecular dimensions); 
H10: 0.05 M KBr, 30% PEG 2000 (JCSG screen, Molecular dimensions); M7: 0.1 M MMT (Malic acid, MES and 
Tris-base buffer) pH 4.0, 25% w/v PEG 1.5 K (microseeding with M8 crystals) (PACT screen, Molecular dimen-
sions); M8: 0.2 M sodium acetate pH 4.6, 2.0 M NaCl (Crystal Screen I/II, Hampton).
Crystals were cryoprotected adding 33% glycerol to mother liquor and then flash frozen in liquid nitrogen. 
X-ray diffraction data were collected at ESRF (European Synchrotron Radiation Facility of Grenoble–France) at 
the beam lines: ID29, ID30, ID23-2, BM14. The diffraction data were analysed and processed using MOSFLM 
and XDS41,42, the crystal symmetry was then verified by POINTLESS43 and the intensities were merged and scaled 
with SCALA44. The crystal structures were determined by molecular replacement using PHASER, BALBES and 
MOLREP45–47. In order to perform the molecular replacement for H7, the full length LC (pdb: 1JVK)10 was used 
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as search model. Then for the subsequent molecular replacements, LC structures determined in house were 
used. H9 initial model was generated by ARP-wARP48. The initial models were subjected firstly to a rigid-body 
refinement and then to a restrained and TLS refinement using Phenix Refine, Refmac5 and Buster49–51. Manual 
model building, water picking and structure analysis were then performed using Coot52. Dimer interface analysis 
shown in Table S3 was performed using PISA53. Fab elbow angles were calculated with phenix.fab_elbow_angle49. 
Figures of crystallographic structures were done using PyMOL and CCP4mg54.
The atomic coordinates and the structure factors of the seven structures of LCs have been deposited in the 
Protein Data Bank with the following accession numbers: 5MTL (H3), 5MUD (H6), 5MUH (H7), 5M6A (H9), 
5M76 (H10), 5MVG (M7), 5M6I (M8).
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H3	 ———	 	 	 	 	 	
H6	 3.06/171	 ———	 	 	 	 	
H7	 1.06/168	 2.95/161	 ———	 	 	 	
H9	 1.28/186	 2.58/174	 1.10/171	 ———	 	 	
H10	 1.41/188	 3.55/183	 1.44/172	 1.68/210	 ———	 	
M8	 3.06/140	 2.65/129	 3.46/122	 2.80/151	 2.72/152	 ———	
	 7	
	
	
Table	S4:	dimer	interface	analysis.	(*):	Energy	gain	on	complex	formation.	
LC	 Solvation	
energy,	chain	
A*		(kcal/mol)	
Solvation	
energy,	chain	
B*		(kcal/mol)	
Dimer	interface	
chain	A	(Å2)	
	
Dimer	interface	
chain	B	(Å2)	
	
H3	 -9.2	 -9.3	 1504	 1486	
H6	 -7.4	 -8.2	 1564	 1568	
H7	 -8.7	 -7.3	 1444	 1347	
H9	 -8.6	 10.8	 1577	 1569	
H10	 -12.1	 -11.3	 1670	 1671	
M7	 -10.2	 -9.1	 1336	 1568	
M8	 -6.8	 -8.7	 1137	 1125	
	 8	
		 														
Figure	S1:	Inspection	of	LC	secondary	and	tertiary	structures.	(A)	panel	A	shows	the	 Far-UV	 CD	 spectra:	 all	 LCs	 display	 spectra	 with	 quite	 comparable	 shapes,	typical	of	proteins	with	high	 -structure	content:	unexpectedly,	the	H7	spectrum,	which	however	is	well	reproducible,	is	atypical	and	not	superposable	to	all	other	spectra.	 Since	 H7	 was	 successfully	 crystallized	 (see	 below)	 and	 showed	cooperative	 unfolding	 curves	 (Figure	 2),	 we	 can	 exclude	 that	 this	 spectrum	indicates	 an	 aggregated	 or	 an	 unfolded	 species.	 Closer	 inspection	 of	 all	 the	 LC	spectra	 shows	 that	 M	 LCs	 cluster	 together,	 displaying,	 on	 average,	 a	 slightly	stronger	 CD	 signal	 (inset),	 as	 if	 the	 M	 LCs	 were	 typically	 characterized	 by	 an	overall	slightly	more	regular	 -structure	in	solution.	(B)	Near-UV	CD	spectra	are	considered	a	tertiary	structure	fingerprint.	The	well	conserved	shape	shared	by	the	recorded	protein	spectra,	suggests	that	LCs	maintain	a	comparable	structure	in	 solution.	 However,	 both	 the	 number	 of	 near-UV	 chromophores	 (mainly	 Trp	and	Tyr	residues)	and	their	chemical	environments	are	not	strongly	conserved	in	 different	 LCs	 due	 to	 sequence	 variability	 in	 the	 VL	 domains.	 Therefore,	 the	resulting	near-UV	CD	spectra	show	expected,	although	unpredictable,	LC-specific	differences,	e.g.	the	M9	spectrum	is	more	intense	than	all	the	other	LCs.		
	 9	
	
Figure	 S2:	 Intermolecular	 disulphide	 bond	 in	 the	 H9	 dimer.	 (A)	 Cartoon	representation	of	the	overall	fold	of	the	H9	homodimer,	having	at	the	C-terminal	a	 disulphide	 bond	 linking	 C215	 the	 two	 LC	 monomers	 (ChainA	 and	 ChainB,	colored	in	grey	and	blue,	respectively).	(B)	Zoom	into	the	well-defined	electron	density	 of	 C215-C215	 disulphide	 bond	 (sticks	 representation)	 and	 the	surrounding	C-terminal	residues	(lines	representation).	2Fo-Fc	electron	density	map	is	contoured	at	1σ.	
	 	
	 10	
	
	
Figure	 S3:	 Plot	 of	 uncleaved	 LC	 at	 the	 end	 of	 the	 proteolysis	 experiments	 as	shown	 in	 Figure	 3A	 (180	 minutes)	 against	 melting	 temperatures	 (Tm)	monitored	by	Far-UV	(see	Table	2).	H	and	M-LCs	are	colour	coded	as	in	Figures	2	and	3.	The	H	and	M	LC	sets	are	circled	highlighting	the	clustering	between	H	and	M	LCs.					
References:	1	 Gertz,	M.	A.	&	Merlini,	G.	Definition	of	organ	involvement	and	response	to	treatment	in	AL	amyloidosis:	an	updated	consensus	opinion	Amyloid	:	the	
international	journal	of	experimental	and	clinical	investigation	:	the	official	
journal	of	the	International	Society	of	Amyloidosis	17,	48	(2010).			
The concurrency of several
biophysical traits links
immunoglobulin light chains with
toxicity in AL amyloidosis
My contribution in this work consisted in summarizing the data 
obtained in order to provide a short overview on our experiments. 
This work has been submitted to Amyloid on July 2018 and it is in 
review.
For Peer Review Only
 
 
 
 
 
 
The concurrency of several biophysical traits links 
immunoglobulin light chains with toxicity in AL amyloidosis 
 
 
Journal: Amyloid 
Manuscript ID DAMY-2018-0173 
Manuscript Type: Letter to the Editor 
Date Submitted by the Author: 30-Jul-2018 
Complete List of Authors: Oberti, Luca; Università degli studi di Milano, Dipartimento di bioscienze 
Maritan, Martina; Università degli studi di Milano, Dipatimento di bioscienze 
Rognoni, Paola; Amyloidosis Research and Treatment Center, Foundation 
Scientific Institute San Matteo, Department of Molecular Medicine, 
University of Pavia 
Barbiroli, Alberto; Universita degli Studi di Milano, DeFens 
Lavatelli, Francesca; Fondazione IRCCS Policlinico San Matteo, Amyloid 
Research and Treatment center 
Russo, Rosaria; Università degli studi di Milano, Dipartimento di bioscienze 
Palladini, Giovanni; University of Pavia and Fondazione IRCCS Policlinico 
San Matteo, Amyloidosis Research and Treatment Center 
Bolognesi, Martino; University of Milan, Dept. of Biosciences 
Merlini, Giampaolo; Amyloidosis Research and Treatment Center, 
Foundation Scientific Institute San Matteo, Department of Molecular 
Medicine, University of Pavia 
Ricagno, Stefano; Università degli studi di Milano, Dipartimento di 
bioscienze 
Keywords: 
Immunoglobulin light chain, Amyloidosis, Biophysics, protein flexibility, fold 
stability 
  
 
 
URL: http://mc.manuscriptcentral.com/damy
Amyloid
For Peer Review Only
The concurrency of several biophysical traits links immunoglobulin light chains 
with toxicity in AL amyloidosis 
 
Luca Oberti
1
, Martina Maritan
1
, Paola Rognoni
2
, Alberto Barbiroli
3
, Francesca Lavatelli
2
, Rosaria 
Russo
4
, Giovanni Palladini
2
, Martino Bolognesi
1
, Giampaolo Merlini
2
 and Stefano Ricagno
1
 
 
1
 Department of Bioscience, University of Milan, Italy, 
2
 Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, and 
Department of Molecular Medicine, University of Pavia, 27100, Pavia, Italy, 
3
 DeFENS - Dep. of Food, Environmental and Nutritional Sciences, University of Milan, Italy, 
4
 Department of  Physiopathology and Transplantation, University of Milan, Italy 
 
Address for correspondence: Stefano Ricagno, Department of Bioscience, University of Milan, Via 
Giovanni Celoria 26, 20133, Milan, Italy. E-mail: stefano.ricagno@unimi.it 
 
Background. Light chain amyloidosis (LC-AL) is the most common systemic amyloidosis. It is 
caused by the overproduction and the aggregation of toxic and monoclonal immunoglobulin light 
chains (LC) in target organs. Among all the organs injured by the pathology, the heart is the most 
affected one. In particular, the ventricular compliance is reduced, resulting in a symptomatic 
congestive heart failure [1]. It is extremely relevant that due to the genetic rearrangement and 
somatic hypermutation, a high variability among LCs’ sequences is generated. This means, 
virtually, that each AL patients present different amyloidogenic LCs [2], stressing in the necessity 
to investigate a large set of cases. To date, it is particularly interesting the observation described in 
Milani et al., 2018 [1], where it was observed that the severity of heart symptoms is linked with the 
blood concentration of full-length LCs, which are the major circulating species. Specifically, these 
facts highlight a crucial role for full-length LC in the pathology beyond the amyloid deposits. 
However, up to now, despite the several works conducted, the molecular bases of proteotoxicity and 
the aggregation mechanism(s) are still unclear.  
 
Material and methods. Our approach consisted in a biophysical and structural characterization. 
LCs were purified from patients’ urine, or by the recombinant expression in E.coli [3]. Protein 
stability was evaluated by circular dichroism (CD) and by anilinonaphthalene-1-sulfonic acid 
(ANS) fluorescence, while flexibility and dynamics was studied by limited proteolysis [3].  The X-
ray diffraction experiments, on LCs crystals, were carried out at the European Synchrotron 
Radiation Facility (ESRF) in Grenoble, France.    
 
Results. In order to achieve as generalizable as possible data, our study is based on a large pool of 
thirteen λ full-length LCs divided in two groups. In particular, eight LCs are amyloidogenic and 
responsible of severe cardiac symptoms in AL patients (H LCs); five are non-amyloidogenic LCs 
and selected from patients affected by multiple myeloma, and used as control (M LCs). In order to 
highlight potential determinants of LCs proteotoxicity and aggregation, all proteins were 
extensively structurally and biophysically characterized. Firstly, X-ray diffraction of seven LCs 
crystals (five H LCs and two M LCs) reveals that H and M LCs structures match very closely. From 
the biophysical point of view, the melting temperature measurements assessed by three independent 
spectroscopic techniques demonstrate that H LCs tend to be less stable than M LCs (fig. 1A). 
Moreover, limited proteolysis by trypsin and protease K strongly indicate that a more pronounced 
flexibility for H LCs compared to M LCs (fig. 1B). These findings suggest thermodynamic 
properties and protein dynamics to have a role in the molecular proteotoxicity mechanism(s). In 
particular, since the crystal structures are conserved, it is very likely that dynamics plays a critical 
role in defining the propensity of a LC to be toxic or not. 
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Recently, Diomede et al., 2017 [4] described H LCs toxicity in vivo to be increased by the presence 
of copper ions. Along this line, we are investigating potential interactions between LCs and bivalent 
cationic metal ions, including copper. In particular, we observe a direct and specific binding 
between H LCs and Cu
2+
. Our findings show that the LC-copper interaction destabilizes the 
proteins and it seems to turn H LCs in a more flexible state, underling the importance of dynamics 
in determining LC toxicity.  
 
Figure 1. A. Average of H LC and M LC melting temperatures. B. Average of the H and M 
uncleaved protein fraction at 180 min after limited proteolysis; *** p-value < 0.0005;                   
**  p-value < 0.005. C. Graphical representation of the biophysical properties contributing in the 
amyloidogenic properties.  
 
Discussion and conclusions. The new contribute of this work highlights the concurrency of 
different biophysical traits to be linked with LCs amyloid propensity. Our data suggest that thermal 
stability and flexibility/dynamics correlate with the proteotoxicity LCs tendency, whereas the 
overall structural determinants are conserved between H and M LCs (fig. 1C). 
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Background. Light chain amyloidosis (AL) is caused by the overproduction, misfolding and 
aggregation of immunoglobulin light chains (LCs) that tend to deposit as amyloid fibrils in 
the cardiac tissue1. Nowadays, the molecular details underling LCs soluble cardiotoxicity 
and fibril formation remain to be fully elucidated. It has been suggested a relationship 
between conformational flexibility and amyloidogenicity, indicating protein thermal stability 
and dynamics as factors able to influence the complex processes of misfolding and 
aggregation2,3. To date, no compelling correlations have been identified between LCs 
cardiotoxicity and primary sequence. Here we present a pivotal mutagenesis study in which 
we produce and characterise a mutated variant of the toxic H6 LC (mH6). Our purpose is to 
abrogate the toxicity typical of H6 yielding to a non-cardiotoxic LC and to understand the 
biophysical and biochemical changes underlying such loss of toxicity.  
 
Material and Methods. H6 mutant design was carried out combining the results of 
bioinformatics tools for protein stability predictions and sequence multi-alignment. H6 
sequence was mutated into mH6 using side directed mutagenesis. E. coli was used to 
express LCs, which are then refolded and purified by chromatographic methods as 
previously reported3. For protein characterization both spectroscopic (Circular Dichroism, 
Fluorescence) and structural (X-ray crystallography) techniques were applied. In-vivo 
toxicity assessment was carried out measuring C. elegans’ pharynx pumping rate4.  
 
Results. The design of mutated H6 was performed applying an innovative method that 
correlates structural data with toxicity (Figure 1). A set of thermal stabilizing mutation 
candidates were found through an hybrid approach involving: i) multi-sequence analysis and 
ii) energetic calculations. H6 amino acid sequence was aligned against a multiple myeloma 
sequence database, in order to identify the conserved amino acids spots associated with non-
toxic LC (Figure 1A). The crystal structure of H6 was analysed by bioinformatics tools that 
calculated the most favourable mutations to achieve protein stabilisation (Figure 1B). Final 
mutations selection was obtained by merging and ranking the best outcomes of the two 
methods (Figure 1C), which led to the identification of three point mutations located in the 
variable domain. 
Preliminary data on mH6 in vivo toxicity seem to indicate a significant decrease in the 
mutant toxic profile compared to the wild type cardiotoxic H6. This points out the critical 
role of specific amino acid positions in determining the toxic behaviour.               
Interestingly, the melting temperatures of H6 and mH6 monitored by Far-UV circular    
dichroism are comparable (Tm H6= 43.9 – 54.5 °C, Tm mH6=53.8 °C). However unfolding 
profiles are not perfectly superposable suggesting different unfolding transitions: mH6 
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appear to have a more defined transition, which possibly reflect a more compact domain 
organization than H6 three step unfolding3. Limited proteolysis data revealed slower 
proteolytic kinetics for the mutant, hence reduced fold stability. 
The crystal structure of mH6 has been determined at 2.1 Å resolution, displaying a 
homodimeric organization common to all LC dimers. Secondary structure superposition 
does not show evident differences between the H6 structure and the mH6 one, giving an 
r.m.s.d. value of 0.3 Å for the overall dimers superposition, indicating that the mutagenesis 
has no impact on the native protein organization and dimerization.  
 
Figure 1. (A) Representative sequence multi-alignment of myeloma LCs against H6.  
Sequence conservation and consensus sequence are depicted by histograms. (B) 
Bioinformatics analysis using H6 structure as input run to identify possible mutation spots. 
(C) The combination of outputs from (A) and (B) lead the mutation spot selection and 
subsequent protein production and characterization. 
 
Discussion and conclusions. Previous biophysical findings indicate that low fold stability 
and high protein dynamics correlate with LC amyloidogenicity3. Our data showed that the 
toxicity of a soluble LC could be tuned by introducing specific point mutations. This 
evidence points out the importance of the primary sequence for cardiotoxic LCs. Moreover, 
our data strengthen the hypothesis that links LCs toxic behaviour in vivo to thermal stability 
and dynamics. 
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